UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2024
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K and
exhibits 99.1, 99.2 and 99.3 are hereby incorporated by reference
into the registrant’s Registration Statements on Form
S-8 (File No. 333-262480) and Form F-3 (File Nos. 333-269306
and 333-260338), to
be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
On June 17, 2024, NeuroSense Therapeutics Ltd. (the “Company”)
changed its accounting method from International Financial Reporting Standards, as issued by the International Accounting Standards Board,
to generally accepted accounting principles in the United States of America (“U.S. GAAP”) as of January 1, 2024. As a result,
the Company re-issued its consolidated financial statements for the year ended December 31, 2023 prepared in accordance with U.S. GAAP.
Such financial statements and accompanying Operating and Financial Review and Prospects
attached hereto replace the consolidated financial statements and the Operating and Financial Review and Prospects included in the Company’s
Annual Report on Form 20-F filed with the SEC on April 4, 2024.
Attached hereto and incorporated by reference
herein are the following exhibits:
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
NeuroSense Therapeutics Ltd. |
|
|
|
Date: June 17, 2024 |
By: |
/s/ Alon Ben-Noon |
|
|
Alon Ben-Noon |
|
|
Chief Executive Officer |
3
Exhibit 99.1
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Shareholders and Board of Directors of
NeuroSense Therapeutics Ltd.
Opinion on the Consolidated Financial Statements
We have audited the accompanying
consolidated balance sheets of NeuroSense Therapeutics Ltd. and its subsidiaries (the “Company”) as of December 31, 2023 and
2022, the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity, and cash flows
for each of the years in the three-year period ended December 31, 2023, and the related notes (collectively, the “consolidated
financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in
the three-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.
Going Concern
The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1B to the consolidated
financial statements, the Company’s recurring losses and its expectation to incur significant additional losses raise substantial
doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note
1B. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Change in Basis of
Accounting
The
Company’s annual consolidated financial statements for 2023 were previously prepared in conformity with International Financial
Reporting Standards as issued by the IASB. As described in Note 1E to the consolidated financial statements, the Company elected to change
the basis of accounting used in preparing its financial statements for it to be in conformity with U.S. generally accepted accounting
principles. Consequently, the Company’s 2023 financial statements including prior years financial statements for 2022 and 2021,
referred to above, are now being presented in accordance with U.S. generally accepted accounting principles.
Basis for Opinion
These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.
/s/ Somekh Chaikin |
|
Somekh Chaikin |
|
Member Firm of KPMG International |
|
We have served as the Company’s auditor since 2020.
Tel-Aviv, Israel
June 17, 2024
NeuroSense Therapeutics Ltd.
Consolidated Balance Sheets
(U.S. dollars in thousands, except share and per share data)
| |
| |
As of December 31, | |
| |
Note | |
2023 | | |
2022 | |
Assets | |
| |
| | |
| |
Current assets: | |
| |
| | |
| |
Cash and cash equivalent | |
3 | |
$ | 2,640 | | |
$ | 3,543 | |
Short term deposits | |
2F | |
| - | | |
| 3,547 | |
Other receivables | |
4 | |
| 236 | | |
| 255 | |
Restricted deposits | |
| |
| 40 | | |
| 36 | |
Total current assets | |
| |
| 2,916 | | |
| 7,381 | |
| |
| |
| | | |
| | |
Non-current assets: | |
| |
| | | |
| | |
Property and equipment, net | |
5 | |
| 85 | | |
| 77 | |
Operating right of use assets | |
6 | |
| 162 | | |
| 236 | |
Restricted deposit | |
| |
| 22 | | |
| 23 | |
Total non-current assets | |
| |
| 269 | | |
| 336 | |
Total assets | |
| |
$ | 3,185 | | |
$ | 7,717 | |
| |
| |
| | | |
| | |
Liabilities and shareholders’ equity | |
| |
| | | |
| | |
Current liabilities: | |
| |
| | | |
| | |
Trade payables | |
| |
$ | 1,459 | | |
$ | 498 | |
Other payables | |
7 | |
| 2,000 | | |
| 1,228 | |
Total current liabilities | |
| |
| 3,459 | | |
| 1,726 | |
| |
| |
| | | |
| | |
Non-current liabilities: | |
| |
| | | |
| | |
Operating long-term lease liability | |
6 | |
| 73 | | |
| 147 | |
Liability in respect of warrants | |
8 | |
| 1,412 | | |
| - | |
| |
| |
| 1,485 | | |
| 147 | |
| |
| |
| | | |
| | |
Total liabilities | |
| |
| 4,944 | | |
| 1,873 | |
| |
| |
| | | |
| | |
Shareholders’ equity: | |
9,10 | |
| | | |
| | |
Authorized: 60,000,000 shares at December 31, 2023 and 2022; Issued and outstanding: 15,379,042 and 11,781,963 shares at December 31, 2023 and 2022, respectively | |
| |
| - | | |
| - | |
Share premium and capital reserve | |
| |
| 24,362 | | |
| 21,858 | |
Accumulated deficit | |
| |
| (26,121 | ) | |
| (16,014 | ) |
Total shareholders’ equity (deficit) | |
| |
| (1,759 | ) | |
| 5,844 | |
Total liabilities and shareholders’ equity | |
| |
$ | 3,185 | | |
$ | 7,717 | |
The accompanying notes are an integral part of
these consolidated financial statements.
NeuroSense Therapeutics Ltd.
Consolidated Statements of Operations and Comprehensive Loss
(U.S. dollars in thousands, except share and per share data)
| |
| |
For the year ended December 31 | |
| |
Note | |
2023 | | |
2022 | | |
2021 | |
Research and development expenses | |
11 | |
$ | (7,274 | ) | |
$ | (5,587 | ) | |
$ | (1,394 | ) |
| |
| |
| | | |
| | | |
| | |
General and administrative expenses | |
12 | |
| (4,775 | ) | |
| (4,967 | ) | |
| (1,591 | ) |
| |
| |
| | | |
| | | |
| | |
Operating loss | |
| |
| (12,049 | ) | |
| (10,554 | ) | |
| (2,985 | ) |
| |
| |
| | | |
| | | |
| | |
Financing income (expenses), net | |
13 | |
| 1,942 | | |
| 62 | | |
| (235 | ) |
| |
| |
| | | |
| | | |
| | |
Net loss and comprehensive loss | |
| |
$ | (10,107 | ) | |
$ | (10,492 | ) | |
$ | (3,220 | ) |
| |
| |
| | | |
| | | |
| | |
Basic and diluted net loss per share | |
| |
$ | (0.74 | ) | |
$ | (0.91 | ) | |
$ | (0.52 | ) |
| |
| |
| | | |
| | | |
| | |
Weighted average number of ordinary shares used in computing basic net loss per share | |
| |
| 13,640,168 | | |
| 11,504,521 | | |
| 6,243,411 | |
The accompanying notes are an integral part of
these consolidated financial statements.
NeuroSense Therapeutics Ltd.
Consolidated Statements of Changes in Shareholders’ Equity
(U.S. dollars in thousands, except share and per share data)
| |
Ordinary Shares | | |
Share
Premium and
Capital | | |
Accumulated | | |
Total Shareholders’
Equity | |
| |
Number | | |
Amount | | |
Reserve | | |
Deficit | | |
(Deficit) | |
Balance as of January 1, 2021 | |
| 5,582,922 | | |
$ | - | | |
$ | 2,961 | | |
$ | (2,302 | ) | |
$ | 659 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of shares in respect of SAFE instruments | |
| 276,672 | | |
| - | | |
| 1,000 | | |
| - | | |
| 1,000 | |
Exercise of warrants and options | |
| 3,083,940 | | |
| - | | |
| 1,311 | | |
| - | | |
| 1,311 | |
Issuance of shares and tradable warrants, net | |
| 2,000,000 | | |
| - | | |
| 8,969 | | |
| - | | |
| 8,969 | |
Share based compensation | |
| - | | |
| - | | |
| 2,115 | | |
| - | | |
| 2,115 | |
Net loss and comprehensive loss | |
| - | | |
| - | | |
| - | | |
| (3,220 | ) | |
| (3,220 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of December 31, 2021 | |
| 10,943,534 | | |
$ | - | | |
$ | 16,356 | | |
$ | (5,522 | ) | |
$ | 10,834 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Repurchase of options | |
| - | | |
| - | | |
| (96 | ) | |
| - | | |
| (96 | ) |
Exercise of warrants and vested RSUs | |
| 838,429 | | |
| - | | |
| 3,870 | | |
| - | | |
| 3,870 | |
Share based compensation | |
| - | | |
| - | | |
| 1,728 | | |
| - | | |
| 1,728 | |
Net loss and comprehensive loss | |
| - | | |
| - | | |
| - | | |
| (10,492 | ) | |
| (10,492 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of December 31, 2022 | |
| 11,781,963 | | |
$ | - | | |
$ | 21,858 | | |
$ | (16,014 | ) | |
$ | 5,844 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of shares and pre-funded warrants, net | |
| 1,333,600 | | |
| - | | |
| 806 | | |
| - | | |
| 806 | |
Exercise of pre-funded warrants, options and vested RSUs | |
| 2,263,479 | | |
| - | | |
| - | | |
| - | | |
| - | |
Share based compensation | |
| - | | |
| - | | |
| 1,698 | | |
| - | | |
| 1,698 | |
Net loss and comprehensive loss | |
| - | | |
| - | | |
| - | | |
| (10,107 | ) | |
| (10,107 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Balance as of December 31, 2023 | |
| 15,379,042 | | |
$ | - | | |
$ | 24,362 | | |
$ | (26,121 | ) | |
$ | (1,759 | ) |
The accompanying notes are an integral part of
these consolidated financial statements.
NeuroSense Therapeutics Ltd.
Consolidated Statements of Cash Flows
(U.S. dollars in thousands, except share and per share data)
| |
For the year ended December 31 | |
| |
2023 | | |
2022 | | |
2021 | |
Cash flows from operating activities | |
| | |
| | |
| |
Net loss for the year | |
$ | (10,107 | ) | |
$ | (10,492 | ) | |
$ | (3,220 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | | |
| | |
Depreciation | |
| 21 | | |
| 12 | | |
| 3 | |
Share based compensation | |
| 1,537 | | |
| 1,728 | | |
| 1,217 | |
Revaluation of liability in respect to warrants | |
| (2,191 | ) | |
| - | | |
| - | |
Revaluation of SAFE instruments | |
| - | | |
| - | | |
| 200 | |
Loss from disposal of property and equipment | |
| - | | |
| - | | |
| 8 | |
Financing expenses (income), net | |
| 473 | | |
| 41 | | |
| (20 | ) |
| |
| | | |
| | | |
| | |
Changes in assets and liabilities: | |
| | | |
| | | |
| | |
Decrease in operating right of use asset | |
| 74 | | |
| 70 | | |
| - | |
Decrease in operating lease liability | |
| (69 | ) | |
| (95 | ) | |
| - | |
Decrease (increase) in other current assets | |
| 19 | | |
| 55 | | |
| (204 | ) |
Increase (decrease) in trade payables | |
| 961 | | |
| 459 | | |
| (16 | ) |
Increase (decrease) in other payables | |
| 928 | | |
| 606 | | |
| 493 | |
| |
| | | |
| | | |
| | |
Net cash used in operating activities | |
| (8,354 | ) | |
| (7,616 | ) | |
| (1,539 | ) |
| |
| | | |
| | | |
| | |
Cash flows from investing activities | |
| | | |
| | | |
| | |
Purchase of property and equipment | |
| (29 | ) | |
| (70 | ) | |
| (17 | ) |
Redemption of (investment in) short-term deposits | |
| 3,500 | | |
| (3,500 | ) | |
| - | |
Investment in restricted deposit, net | |
| (3 | ) | |
| (20 | ) | |
| - | |
| |
| | | |
| | | |
| | |
Net cash provided by (used in) investing activities | |
| 3,468 | | |
| (3,590 | ) | |
| (17 | ) |
| |
| | | |
| | | |
| | |
Cash flows from financing activities | |
| | | |
| | | |
| | |
Issuance of SAFE instruments | |
| - | | |
| - | | |
| 800 | |
Payment in respect of cancellation of options | |
| - | | |
| (96 | ) | |
| - | |
Exercise of warrants and options | |
| 5 | | |
| 3,870 | | |
| 1,238 | |
Issuance of shares, warrants and pre-funded warrants, net | |
| 3,970 | | |
| - | | |
| 9,864 | |
| |
| | | |
| | | |
| | |
Net cash provided by financing activities | |
| 3,975 | | |
| 3,774 | | |
| 11,902 | |
| |
| | | |
| | | |
| | |
Effects of exchange rate changes on cash and cash equivalents | |
| 8 | | |
| (88 | ) | |
| 18 | |
Increase (decrease) in cash and cash equivalents | |
| (903 | ) | |
| (7,520 | ) | |
| 10,364 | |
| |
| | | |
| | | |
| | |
Cash and cash equivalents as at the beginning of the year | |
| 3,543 | | |
| 11,063 | | |
| 699 | |
| |
| | | |
| | | |
| | |
Cash and cash equivalents as of the end of the year | |
$ | 2,640 | | |
$ | 3,543 | | |
$ | 11,063 | |
| |
| | | |
| | | |
| | |
Non-cash investing and financing activities: | |
| | | |
| | | |
| | |
Recognition of right of use assets | |
$ | - | | |
$ | 306 | | |
$ | - | |
Conversion of SAFE instruments | |
$ | - | | |
$ | - | | |
$ | 1,000 | |
Supplemental disclosure of cash flow information: | |
| | | |
| | | |
| | |
Interest received | |
$ | 179 | | |
$ | 49 | | |
$ | - | |
The accompanying notes are an integral part of
these consolidated financial statements.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 1 - General
A. |
NeuroSense Therapeutics Ltd. (“NeuroSense” or the “Company”) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs. |
In addition to PrimeC, the Company
has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease, with a similar strategy of
combined products.
The Company’s ordinary shares
and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbols “NRSN” and
“NRSNW,” respectively.
B. |
The Company currently has no products approved for sale and the Company’s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company’s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. |
Based on current expected level of
operating expenditures, the Company’s cash resources as at December 31, 2023 and the cash received after the reporting period (see
also Note 16) shall not be sufficient to fund the Company’s operations for a period of at least 12 months from the approval of these
consolidated financial statements, assuming that the Company will continue its development plan in accordance with the original pipeline
and without delaying or slowing down the progress of its plans. The Company will require additional cash to fund the execution of its
mid and long-term development program. The Company anticipates raising additional funds through public or private sales of debt or equity
securities, collaborative arrangements, or some combination thereof. Whilst management is progressing with its plans to secure external
financing, these still require approval by third parties, and accordingly, there is no assurance that any such arrangement will be entered
into or that financing will be available when needed in order to allow it to continue its operations, or if available, on terms favorable
or acceptable to it.
In the event financing is not obtained,
the Company may pursue cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs
or clinical trials, these events could have a material adverse effect on its business. These factors raise significant doubt about
the Company ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company
be unable to continue as a going concern.
C. |
On October 3, 2022, the Company established a US based subsidiary, NeuroSense US Inc. (“US Subsidiary”). From establishment through December 31, 2023, the US Subsidiary had no activity. The subsidiary will perform research and development activity and engage in possible collaboration agreements. On July, 2023, the Company established a German based subsidiary, NeuroSense GmbH (“NeuroSense GmbH “). NeuroSense GmbH will perform research and development activity and engage in possible collaboration agreements. From establishment through December 31, 2023, NeuroSense GmbH had no activity. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 1 - General (cont.)
D. |
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets, launched extensive rocket attacks and kidnapped many Israeli civilians and soldiers. Following the attack, Israel declared war against Hamas. In parallel, border clashes between Israel and the Hezbollah terrorist group on Israel’s northern border with Lebanon intensified and may escalate into a greater regional conflict. |
All of the Company’s clinical
and pre-clinical research and development is currently being conducted outside of Israel, other than its 12-month
open label-extension (“OLE”) study of the PARADIGM trial, partially conducted in Tel Aviv, and a Phase
2 trial for Alzheimer’s disease that we conduct in Haifa, Israel. The OLE has not been affected by the war, although
the quality of the study may be adversely affected if as a result of the war patients are unable to visit the study center or the study
coordinator is not able to conduct home visits and monitor the patients. In addition, in the event of a significant escalation of
hostilities in northern Israel, there may be a delay in the planned Alzheimer trial. The Company may also elect to set
up a site in Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to numerous other sites in Europe and the
U.S., and as a result it does not expect the timeline or quality of this trial to be adversely affected by the war.
The Israel Defence Force (the “IDF”),
the national military of Israel, is a conscripted military service, subject to certain exceptions. Since October 7, 2023, the IDF has
called up several hundred thousand of its reserve forces to serve. Fourteen out of the Company’s current 16 employees are resident
in Israel. Two of its non-management employees in Israel who do not perform critical functions have been called, and additional employees
may be called, for service in the current or future wars or other armed conflicts with Hamas or other terrorist groups, and such persons
may be absent for an extended period of time. As a result, its operations in Israel may be disrupted by such absences, which disruption
may materially and adversely affect its business, prospects, financial condition and results of operations.
Although until approval of these financial
statements, the impact of the war on the Company was negligible, it is currently not possible to predict the duration or severity of the
ongoing conflict or its effects on the Company’s business, operations and financial conditions. The ongoing conflict is rapidly
evolving and developing, and could disrupt its business and operations, and hamper its ability to raise additional funds or sell its securities,
among others.
E. |
After the Company issued its annual financial
statements for 2023 in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International
Accounting Standards Board, the Company elected to change the basis of accounting used in preparing its financial statements from IFRS
to United States generally accepted accounting principles (“U.S. GAAP”). Consequently, the Company’s 2023 financial
statements including prior years financial statements for 2022 and 2021 have been re-presented in accordance with U.S. GAAP.
In these financial statements, the Company has
applied U.S. GAAP as issued by the Financial Accounting Standards Board, or FASB, on a fully retrospective basis. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 2 - Significant Accounting Policy
The consolidated financial statements
have been prepared in accordance accounting principles generally accepted in the United States of America (“US GAAP”).
B. | Use of estimates in preparation of consolidated financial statements |
The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company’s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company’s
operation, is the U.S. dollar (“$” or “dollar”), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.
In accordance with ASC 830, “Foreign
Currency Matters”, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.
D. | Principles of Consolidation |
The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.
E. | Cash and cash equivalents |
Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.
Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.
Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 2 - Significant Accounting Policy (cont.)
H. | Property and equipment |
Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.
The Company’s long-lived assets are
reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.
The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:
| |
% |
Computers and peripherals and equipment | |
33 |
Office furniture and equipment | |
7 - 15 |
Leasehold improvements | |
The shorter of the lease term and the useful life |
I. | Research and Development |
Research and development costs are
expensed as incurred.
J. | Fair Value Measurements |
The Company measures and discloses
fair value in accordance with the ASC 820, “Fair Value Measurements and Disclosures” which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.
Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.
This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
As of the reported periods, the fair
values of the Company’s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company’s
consolidated balance sheets because of their nature.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 2 - Significant Accounting Policy (cont.)
K. | Concentrations of credit risk |
Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).
The Company applies ASC 842, “Leases”
under which the Company determines if an arrangement is a lease at inception. The Company’s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.
Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.
Right of Use (“ROU”) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (“IBR”) based on the information available
on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment
- Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.
M. | Commitment and contingencies |
The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 2 - Significant Accounting Policy (cont.)
N. | Employee benefit plans |
The Company’s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (“Section 14”), pursuant
to which all of the Company’s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee’s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2023 have been made.
The Company accounts for income taxes
in accordance with ASC 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities
under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences
reverse. Valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred tax assets is amounts
more likely than not to be realized.
The Company implements a two-step approach
to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax
return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical
merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company’s
accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did
not recognize such items in its consolidated financial statements during the reported periods and did not recognize any liability with
respect to an unrecognized tax position in its balance sheets.
Taxes which would apply in the event
of disposal of investment in foreign subsidiaries have not been considered in computing the deferred taxes, since the intention of the
Company is to hold and not to realize the investment.
P. | Stock-based compensation |
The Company’s employees’
and directors’ share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.
For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.
Q. | Basic and diluted net loss per share |
Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001 which
are exercisable immediately and fully vested RSUs outstanding during the period.
Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.
During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 2 - Significant Accounting Policy (cont.)
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.
S. | Recently adopted accounting pronouncements |
| 1. | In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit
Losses (“ASC 326”): Measurement of Credit Losses on Financial Instruments” to introduce a new model for recognizing
credit losses on financial instruments based on estimated current expected credit losses, or CECL. Under the new standard, an entity is
required to estimate CECL on trade receivables at inception, based on historical information, current conditions, and reasonable and supportable
forecasts. The guidance is effective for the Company for annual periods beginning after December 15, 2022, including interim periods within
those fiscal years. Early application is permitted. The Company adopted this guidance on January 1, 2023, and there was no material impact
on the Company’s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
| 2. | In August 2020, the FASB issued ASU 2020-06 “Debt- Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”): Accounting
for Convertible Instruments and Contracts in an Entity’s Own Equity”. This guidance simplifies the accounting for certain
financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s
own equity. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per
share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15, 2023, and interim periods within
those fiscal years. The Company plan to adopt this guidance on January 1, 2024, and there was no material impact on the Company’s
consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
T. | Recently issued accounting pronouncements, not yet adopted |
As an emerging growth company, the
Jumpstart Our Business Startup Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.
| 1. | In December 2023, the FASB issued ASU 2023-09 “Improvements to Income Tax Disclosures” which improves the transparency
of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation
and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income tax disclosures effectiveness.
The guidance is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company
is currently evaluating the potential effect that the updated standard will have on the consolidated financial statement disclosures. |
| 2. | In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures” which
expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly
provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description
of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public
entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280.
The guidance is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January
1, 2025, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
financial statements and related disclosures. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 3 - Cash and cash equivalent
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
U.S. dollars in thousands | |
Denominated in NIS | |
$ | 107 | | |
$ | 229 | |
Denominated in USD | |
| *2,533 | | |
| 3,309 | |
Denominated in EUR | |
| - | | |
| 1 | |
Denominated in GBP | |
| - | | |
| 4 | |
| |
$ | 2,640 | | |
$ | 3,543 | |
Note 4 - Other receivables
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
U.S. dollars in thousands | |
Government agencies | |
$ | 29 | | |
$ | 24 | |
Prepaid expenses | |
| 70 | | |
| 124 | |
Other | |
| 137 | | |
| 107 | |
| |
$ | 236 | | |
$ | 255 | |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 5 - Property and equipment, net
Balance as of December 31, 2023:
| |
Computers and
peripherals and
equipment | | |
Office
furniture and
equipment | | |
Leasehold
improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2023 | |
$ | 66 | | |
$ | 25 | | |
$ | 3 | | |
$ | 94 | |
Purchases during the year | |
| 26 | | |
| 3 | | |
| - | | |
| 29 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 92 | | |
| 28 | | |
| 3 | | |
| 123 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2023 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
Depreciation during the year | |
| 20 | | |
| 1 | | |
| (*) | | |
| 21 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 34 | | |
| 4 | | |
| (*) | | |
| 38 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2023 | |
$ | 58 | | |
$ | 24 | | |
$ | 3 | | |
$ | 85 | |
Balance as of December 31, 2022:
| |
Computers and peripherals and
equipment | | |
Office furniture and
equipment | | |
Leasehold improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2022 | |
$ | 8 | | |
$ | 16 | | |
$ | - | | |
$ | 24 | |
Purchases during the year | |
| 58 | | |
| 9 | | |
| 3 | | |
| 70 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 66 | | |
| 25 | | |
| 3 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2022 | |
| 4 | | |
| 1 | | |
| - | | |
| 5 | |
Depreciation during the year | |
| 10 | | |
| 2 | | |
| - | | |
| 12 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2022 | |
$ | 52 | | |
$ | 22 | | |
$ | 3 | | |
$ | 77 | |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 6 - Operating lease
The Company has lease agreements with respect
to offices. In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent
payments including utilities amount to approximately $7 thousand and indexed to CPI. The lease period is for 24 months with an option
to extend the lease period for additional two periods of 24 months each (the first one was exercised by the Company). Accordingly, the
Company recognized in the consolidated balance sheet a right-of-use asset in the amount of $306 thousand concurrently with the recognition
of a lease liability in the same amount.
Operating lease:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Operating right of use asset | |
$ | 162 | |
Current operating lease liability | |
$ | 69 | |
Non-Current operating lease liability | |
$ | 73 | |
Total operating lease liability | |
$ | 142 | |
Maturity analysis of the Company’s lease liability:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Less than one year | |
$ | 74 | |
Two years | |
| 78 | |
| |
| | |
Total operating lease payments | |
$ | 152 | |
| |
| | |
Less: imputed interest | |
$ | (10 | ) |
| |
| | |
Present value of lease liabilities | |
$ | 142 | |
Additional information on lease
The following is a summary of weighted average
remaining lease terms and discount rate for Company’s leases:
| | December 31, 2023 | |
Lease term (years) | | | 2 | |
Weighted average discount rate | | | 6 | % |
Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2023, 2022 and 2021:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Lease payments | |
| 75 | | |
| 79 | | |
| - | |
| |
$ | 75 | | |
$ | 79 | | |
$ | - | |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 7 - Other payables
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Employees and payroll accruals | |
$ | 1,481 | | |
$ | 751 | |
Short term lease liability | |
| 69 | | |
| 64 | |
Accrued expenses | |
| 450 | | |
| 413 | |
| |
$ | 2,000 | | |
$ | 1,228 | |
Note 8 - Liability in respect of warrants
As noted in Note 9Ah below, on June 22, 2023,
the Company entered into a registered direct offering under which, inter alia, the Company issued to institutional purchaser 3,000,000
warrants, each representing the right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash
basis at the Purchaser’s discretion) and will expire on the fifth anniversary of the original issuance date. The warrants are not
considered indexed to the Company’s own stock and thus have been accounted as financial liability measured at fair-value through profit
and losses until their expiration or exercise.
The Company’s financial measured at fair
value on a recurring basis, consisted of the following types of instruments as of the following dates:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Description | |
Fair value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liability in respect of warrants | |
$ | 1,412 | | |
$ | - | | |
$ | 1,412 | (*) | |
$ | - | |
| |
December 31, 2023 | |
Financial liabilities: | |
| |
Expected volatility (%) | |
| 93.91 | |
Share price (in $) | |
| 0.785 | |
Risk-free interest rate (%) | |
| 3.90 | |
Expected life (years) | |
| 4.47 | |
Dividend yield (%) | |
| - | |
| |
| | |
The following table summarizes the movement in warrant liability during
the year ended December 31, 2023:
| |
2023 | |
| |
U.S. dollars in thousands | |
| |
| |
Balance as at January 1, 2023 | |
$ | - | |
Recognition of liability in respect to warrants at the initial date | |
| 3,603 | |
Revaluation of liability in respect to warrants | |
| (2,191 | ) |
Balance as at December 31, 2023 | |
$ | 1,412 | |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 9 - Shareholders’ Equity
| |
Number of shares December 31 | |
| |
Authorized 2023 | | |
Issued and outstanding 2023 | | |
Authorized 2022 | | |
Issued and outstanding 2022 | |
Ordinary shares of no par value | |
| 60,000,000 | | |
| 15,379,042 | | |
| 60,000,000 | | |
| 11,781,963 | |
| a. | In February, May, June and July 2021, the Company entered into Simple Agreements for Future Equity (each, a “SAFE”) with four separate investors for aggregate proceeds of $800 thousand. Pursuant to the terms of each SAFE, upon consummation of an equity financing, the Company will issue to each investor the number of ordinary shares equal to the purchase amount divided by the SAFE price, which is defined as the price per share equal to 80% of the equity financing valuation (to be no less than $25,000 thousand). The SAFE Agreements also provide the investor the right to automatically receive ordinary shares in the case of a liquidity event, defined as a change of control event or an initial public offering. In the case of a liquidity event the investors are entitled to the number of ordinary shares equal to the investment amount divided by the liquidity price. The liquidity price is defined as the price per share equal to the Company’s valuation at the time of the liquidity event, multiplied by 80%, and divided by the Company’s capitalization (to be no less than $25,000 thousand). The Company accounted for the SAFE instrument as financial liability in accordance with ASC 480-10. The Company recorded financial expenses in the amount of $200 thousands in 2021. |
| b. | During 2018 and 2019, the Company entered into several Share Purchase Agreements (“SPAs”) with multiple investors pursuant to which the Company issued shares and warrants. Pursuant to the SPAs, the warrants had an exercise price of $0.67 and were set to expire on December 31, 2020. During 2020, the board of directors extended the expiration period for each warrant to December 31, 2021. In September 2021, three of the warrant holders assigned all or part of their warrants to four assignees, among whom are the Company’s CFO and related parties of the Company’s CEO and CFO). |
In August and September 2021 after
the said assignments, the Company received warrant exercise notices of 1,837,500 warrants, out of the total 2,130,000 warrants
outstanding at that time. The other 292,500 warrants that were not exercised were waived by their owners. As a result of the said
exercises, the Company received aggregate proceeds of $1,225 thousand.
| c. | In May and October 2021, several option holders exercised their outstanding options to purchase 285,000 ordinary shares for a gross proceed of $10 thousand. |
| d. | In October 2021, several option holders, holding an aggregate amount of 961,440 options, signed an exercise notice for their options. The proceeds from such options exercise were approximately $76 thousand. As of December 31, 2023, the amount of $47 thousand from such exercises were recognized as other receivables. |
| e. | In December 2021, the Company closed its IPO in the United States and issued 2,000,000 units consisting of 2,000,000 Ordinary shares and 2,000,000 tradable warrants with an exercise price of $6 per share, and in term of 5 years. The total gross consideration was $12,000 thousand. The above warrants was classified to equity and the gross consideration received were allocated entirely to shareholders’ equity. Applicable issuance costs, amounting to $2,136 thousand and share-based issuance costs, amounting to $898 thousand have been allocated entirely to shareholders’ equity. In addition, the net proceeds from the exercise of underwriter’s option were $3 thousand. |
| f. | In March 2022, the Company received an amount of $3,870 thousand as a result of the exercise of 645,000 warrants at a price per share of $6. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 9 - Shareholders’ Equity (cont.)
| g. | On April 14, 2023, the Company entered into a sales agreement with Alliance Global Partners, pursuant to which the Company may offer and sell, from time to time, to or through the Alliance Global Partners as agent or principal, ordinary shares an at-the-market offering, having an aggregate offering price of up to $5,744 thousands. On June 22, 2023, the Company filed a prospectus supplement reflecting a reduction in the size of the at-the-market offering to $502 thousands. During the reporting period, the Company sold 3,600 ordinary shares for a gross proceed of $7 thousands through the at-the-market offering. Issuance expenses were equal to the proceeds received. |
| h. | On June 22, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) an aggregate of 1,330,000 ordinary shares, no par value, and (ii) an aggregate of 1,670,000 Pre-Funded warrants, each representing the right to acquire one ordinary share with exercise price of $0.0001, exercisable at any time until exercised in full and (iii) an aggregate of 3,000,000 Warrants. The Warrants are exercisable immediately upon issuance at an exercise price of $1.50 per Ordinary Share and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.5 million before deducting the placement agent fee and related offering expenses of $455 thousands. The warrant instrument is classified as liability with an original fair value in the amount of $3,603 thousands and the remaining amount of $897 thousands was attributed to the ordinary shares and pre-funded warrants and recognized in equity. The direct incremental issuance costs, amounting to $454 thousands, have been allocated in the same proportion as the gross proceeds. An amount of $365 thousands was allocated to the ordinary warrants and carried directly to profit or loss as finance expense and an amount of $91 thousands was allocated to the ordinary shares and the pre-funded warrants and recognized as a reduction of equity. |
| i. | On June 23, 2023, one of the Company’s employees exercised 126,000 options into 126,000 ordinary shares for a total consideration of $5 thousands. |
| j. | During October 2023, 1,670,000 Pre-Funded warrants were exercised into 1,670,000 ordinary shares of the Company. See also Note 9Ah above. |
Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board
of directors, subject to the prior rights of holders of all classes of shares outstanding.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 10 - Share Based Payment
On December 16, 2018, the Company’s board
of directors approved an employee share option plan (“ESOP”). According to the provisions of the ESOP, the exercise period,
exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company’s fiscal year, equal to 4% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan.
The expiration date of the options granted to
employees and directors is after 10 years from the grant date. Relating to options granted to services providers, the expiration date
of the options is between 3-10 years from the grant date. In addition, pursuant to the grant letters, the options granted to employees,
directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent
party as described in the grant letters (“Exit Event”).
On October 31, 2021, the Company’s
board of directors approved an amendment to the Company’s 2018 Employee Share Option Plan. The amendment determines that the total
number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be:
| ● | An annual increase to be added as of the first day of the Company’s fiscal year, beginning in 2022 and occurring each year thereafter through 2032, equal to 4% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the Company’s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors in its sole discretion). |
Following this amendment, the number of shares
reserved under this plan was 1,151,130. As of December 31, 2023, 233,543 ordinary shares are available for future grant.
1. | In March 2021, the Company’s board of directors approved the grant of 15,000 options to a certain service provider of the Company. The options had an exercise price of $1.67 per share. The options were to vest quarterly over one year starting June 2021. On October 31, 2021, the Company’s board of directors approved a new grant to such service provider. Accordingly, the Company granted 22,500 options with the following terms: |
| ● | 10,500 options have an exercise price of $1.67 per share. The options vest immediately upon an IPO. |
| ● | 6,000 options have an exercise price of $1.67 per share. The options vested on December 15, 2021. |
| ● | 6,000 options have an exercise price of $1.67 per share. The options vested on March 15, 2022. |
The options are exercisable if the
Company receives services from the service provider during the mentioned period.
The Company accounted the new grant
as a modification to the existing grant.
2. | In July 2021, the Company granted 21,000 options to the Company’s chief financial officer. The options have an exercise price of $0.03 per share. The options vest monthly over seven months starting June 2021. Pursuant to his employment agreement, the Company agreed that to the extent the value of such options at the Company’s IPO is less than $200,000, the Company shall grant additional options. In October 2022, the Company granted 35,980 RSU’s is respect with the above. |
3. | In August 2021, the Company’s board of directors approved the grant of 9,000 options to an employee. The options have an exercise price of $5.33 per share. The options vest quarterly over 3 years starting September 2021. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 10 - Share Based Payment (cont.)
4. |
On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved the following awards to the Company’s current management and directors subject to an IPO: |
| ● | 108,000 RSUs to each of the Company’s Chief Executive Officer and Chief Financial Officer, which vest on a quarterly basis over 3 years, commencing December 13, 2021. |
| ● | 192,000 options to the Chairman of the Board. The options vest over four years on a quarterly basis commencing October 1, 2021 at an exercise price equal to $3.51. |
| | |
| ● | 72,000 options to a director. The options have an exercise price of $3.51 per share. The commencement date of the Option’s is December 13, 2021 (the “Vesting Commencement Date”). The Options vest as follows: one-third vest one year from the Commencement Date and the remainder vest quarterly over the following two year period. |
5. | On October 31, 2021, the Company’s board of directors approved the grant of 108,000 options to the Company’s Chief Medical Officer. The options have an exercise price of $3.51 per share and vest on a quarterly basis over 3 years starting December 2021. |
6. |
On November 9, 2021, the Company’s board of directors approved the extension of the exercise period of options of two employees, which, pursuant to their original terms would have been expire if not exercised before the completion of the IPO. According to the grant letter, at the event of an IPO, all unvested options were fully vested, and accordingly, the remaining unrecognized expenses were recorded immediately upon such vesting. |
7. | On December 9, 2021, the underwriter (see Note 9Ae), partially exercised its right to purchase an additional 300,000 warrants for a total consideration of $3 thousands. The warrants have an exercise price of $6 per share and expire 5 years after the issuance date. These warrants were treated as issuance costs, which amounted to $681 thousand based on third party valuation, and have been recorded in equity as a reduction of the share premium. Furthermore, as part of the offering, the Company issued 100,000 warrants to the underwriters as share-based issuance costs. The warrants have an exercise price of $7.5 per share and expire 5 years after date of issuance and can be exercised after June 8, 2022. These options were also treated as issuance costs and amounted to $217 thousand based on third party valuation. |
8. | On December 13, 2021, upon the completion of the Company’s IPO, 961,440 options were exercised into shares (refer to Note 9Ad above) and 20,130 Options were expired. Those options previously granted to Company’s service providers, which, according to their grants, are vested upon a successful consummation of the IPO and the remaining unrecognized expenses were recorded immediately upon such vesting. |
| |
9. | On January 10 and January 11, 2022, the Company’s entered into option settlement agreement (“Agreements”) with certain consultants of the Company. According to the Agreements, the Company exchanged 27,000 options granted to certain consultants with cash payments in the aggregate of $96 thousands. The cash payment is deemed as the sole and complete settlement of the promised options. The Company recorded an additional expense of $23 thousand for such settlement which was recorded in profit and loss. The Company recorded the settlement agreement as a reduction in share premium and capital reserve. |
10. | On January 25, 2022 and March 10, 2022, the Company’s board of directors and shareholders, respectively, approved the compensation of each of the Company’s external directors and a newly appointed director. Such compensation included the grant of 72,000 options to each such director at an exercise price of $1.43 per share (total 216,000 options to three directors), pursuant to the Company’s 2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly and becomes fully vested three years from the grant date. The options expire 10 years after grant date. |
11. | On January 25, 2022, the Company’s board of directors approved the grant of aggregate amount of 192,000 options to several employees. The options have an exercise price of $2.18 per share. The options vest quarterly over three years starting January 25, 2022. The options expire 10 years after grant date. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 10 - Share Based Payment (cont.)
12. | In March 2022, the Company’s board of directors approved the grant of aggregate amount of 36,000 options to an employee and amount of 5,000 options consultant of the Company. The options have an exercise price of $3.97 and $2.18, respectively, per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date. |
13. | In July and August 2022, the Company’s board of directors approved the grant of aggregate amount of 20,000 options to a consultant and an amount of 120,000 options to several employees of the Company. The options have an exercise price of $2.18 and $1.99, respectively, per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date. |
14. | During 2022 the Company issued 85,449 of its ordinary shares to certain consultants in exchange for their services, with fair value of $119 thousands. One of the consultants received 44,000 shares of restricted stock which were issued in 4 equal installments and subject to 2 year lock-up period. Other consultant’s shares are subject to 6 months restriction period (which ended by December 31, 2022). |
15. | On March 20, 2023, the Company’s board of directors, approved the following awards: |
| ● | Grant of 320,479 RSUs to certain officers, in lieu of cash with respect to the 2022 bonus plan grants in the amount of $161 thousand. The RSUs vest quarterly over two years with acceleration condition upon meeting certain milestones. The Company met the milestones in 2023 and therefore the vesting was accelerated accordingly. |
| ● | A bonus for certain employees in the form of 100,000 and 60,000 RSU’s. The RSUs vest on a quarterly basis over one year following the grant and on an annual basis over three years following the grant, respectively. |
| ● | In addition to the grants in accordance with the 2022 bonus plan mentioned above, a raise of additional 30% of the annual 2022 bonus will be granted to the Company’s CEO. |
| ● | The grant of 13,628 Options to a consultant of the Company in in a total fair value of $22,500. The options have an exercise price of $1.82 per share. The options will vest monthly, over 9 months commencing January 1, 2023. The options expire 10 years after their grant date. |
16. | On May 30, 2023, the Company granted 160,000 RSUs to directors of the Company. The RSUs have an exercise
price of $1.53 per share. The RSUs shall vest entirely on the first anniversary of the vesting commencement date, provided that no termination
of employment of the grantee occurs prior to such anniversary. |
17. | On August 15, 2023, the Company’s board of directors approved the grant of aggregate amount of 60,000
options to several employees. The options have an exercise price of $0.96 per share and vest quarterly over 3 years starting August 15,
2023, and (ii) the grant of 9,000 options to an employee. The options have an exercise price of $0.96 per share and vest annually over
3 years starting August 15, 2023. |
The weighted average grant date fair value of
options granted during the years ended December 31, 2023, 2022 and 2021 was $0.80, $1.40 and $4.33 per option, respectively. The
weighted average grant date fair value of RSUs granted during the years ended December 31, 2023 and 2021 was $1.75 and $3.72 per
RSU, respectively.
Stock-based compensation expenses recognized in
profit and loss as an operating expense based on fair value of the option at the grant date by using Binominal option pricing model for
employees and directors and Black and scholes pricing model for non-employees. The inputs for the valuation analysis of the share options
include several assumptions of which the most significant are the fair market value of the underlying ordinary share, the expected share
price volatility and the expected option term. Expected volatility was calculated based upon historical volatility of peer companies in
the same industry on weekly basis. Expected option term represents the period that the Company’s share options are expected to be
outstanding and is set as an exercise coefficient based on academic empirical papers. Risk-free interest rate is based on the yield from
U.S. treasury bonds with an equivalent term. Expected dividend yield assumption is based on the Company’s historical experience
and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay
cash dividends in the future. Forfeitures are recognized as they occur.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 10 - Share Based Payment (cont.)
The following table lists the inputs used for
calculation of fair value of the options granted to employees and directors for the years ended December 31, 2023, 2022 and 2021:
| |
2023 | |
2022 | |
2021 |
Expected volatility | |
91.80% - 93.51% | |
93.63% - 93.79% | |
91.60% - 95.01% |
Exercise price | |
0.96 - 1.99 | |
1.43 - 3.97 | |
0.03 - 5.33 |
Share price (1) | |
0.96 - 1.99 | |
1.43 - 3.97 | |
3.72 - 18.19 |
Risk-free interest rate | |
3.24% - 4.35% | |
2.12% - 2.46% | |
1.42% - 1.81% |
Dividend yield | |
0 | |
0 | |
0 |
Expected life (years) | |
10 | |
10 | |
10 |
The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2023, 2022 and 2021:
| | 2023 | | 2022 | | 2021 |
Expected volatility | | 100.540% | | 93.64% | | 94.25% - 94.90% |
Exercise price | | 1.82 | | 2.18 | | 1.67 |
Share price (1) | | 1.82 | | 1.41 - 1.96 | | 3.72 - 15.16 |
Risk-free interest rate | | 3.64% | | 1.91% - 2.91% | | 1.68% - 1.72% |
Dividend yield | | 0 | | 0 | | 0 |
Expected life (years) | | 10 | | 10 | | 10 |
The following table lists the inputs used for calculation of fair value
of the underwriters warrants granted for the year ended December 31, 2021:
Expected volatility | | | 90.59 | % |
Exercise price | | $ | 7.5 | |
Share price | | $ | 3.72 | |
Risk-free interest rate | | | 1.23 | % |
Dividend yield | | | 0 | |
Expected life | | | 5 | |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 10 - Share Based Payment (cont.)
The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2023 and 2022:
| | Number of | | | Weighted Average | | | Weighted average remaining | | | Intrinsic value | |
| | Share Options | | | Exercise Price | | | contractual life (years) | | | U.S. dollars in thousands | |
Options outstanding at January 1, 2023 | | | 1,160,500 | | | $ | 2.16 | | | | 8.76 | | | $ | 247 | |
Granted | | | 82,628 | | | $ | 1.10 | | | | | | | | | |
Exercised | | | (126,000 | ) | | | 0.03 | | | | | | | | | |
Forfeited | | | (48,000 | ) | | $ | 2.09 | | | | | | | | | |
Options outstanding at December 31, 2023 | | | 1,069,128 | | | $ | 2.30 | | | | 8.15 | | | $ | 62 | |
Exercisable at December 31, 2023 | | | 652,878 | | | $ | 2.26 | | | | 8.00 | | | $ | 62 | |
The following table summarizes the RSU’s activity for the annual
periods ended on December 31, 2023 and 2022:
| |
| | |
Weighted average grant date fair value | |
| |
Number of RSUs | | |
U.S. dollars in thousands | |
Outstanding at January 1, 2023 | |
| 144,000 | | |
$ | 176 | |
Granted | |
| 640,479 | | |
| | |
Exercised | |
| (467,479 | ) | |
| | |
Outstanding at December 31, 2023 | |
| 317,000 | | |
$ | 249 | |
The share-based expense recognized in the statements of operations
were as follows:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Share-based compensation expense - Research and development | |
$ | 575 | | |
$ | 570 | | |
$ | 281 | |
Share-based compensation expense - General and administrative | |
| 962 | | |
| 1,158 | | |
| 936 | |
| |
$ | 1,537 | | |
$ | 1,728 | | |
$ | 1,217 | |
During 2021, in addition to the share-based compensation
expenses that have been recorded in profit and loss, share-based compensation in the amount of $898 thousands has been allocated to the
issuance of shares and tradable warrants and accordingly recorded as a reduction of the share premium.
As of December 31, 2023, there was $376 thousands
of unrecognized compensation expense related to unvested options and RSUs. Such unrecognized expenses will be recognized over a weighted
average period of approximately 0.59 years.
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 11 - Research and development expenses
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Subcontractors and consultants | |
$ | 4,793 | | |
$ | 3,612 | | |
$ | 628 | |
Share-based compensation | |
| 575 | | |
| 570 | | |
| 281 | |
Salaries and social benefits (*) | |
| 1,905 | | |
| 1,405 | | |
| 447 | |
Others | |
| 1 | | |
| - | | |
| 38 | |
| |
$ | 7,274 | | |
$ | 5,587 | | |
$ | 1,394 | |
Note 12 - General and Administrative Expenses
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Professional services | |
$ | 1,486 | | |
$ | 1,085 | | |
$ | 372 | |
Share-based compensation | |
| 962 | | |
| 1,158 | | |
| 936 | |
Salaries and social benefits (*) | |
| 1,011 | | |
| 1,014 | | |
| 74 | |
Insurance | |
| 511 | | |
| 1,174 | | |
| 68 | |
Traveling abroad | |
| 164 | | |
| 165 | | |
| 50 | |
Others | |
| 641 | | |
| 371 | | |
| 91 | |
| |
$ | 4,775 | | |
$ | 4,967 | | |
$ | 1,591 | |
Note 13 - Financing Income (expenses), net
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Finance Income: | |
| | |
| | |
| |
Revaluation of warrants | |
$ | 2,191 | | |
$ | - | | |
$ | - | |
Deposit interest | |
| 178 | | |
| 91 | | |
| - | |
Exchange rates | |
| 21 | | |
| - | | |
| - | |
| |
$ | 2,390 | | |
$ | 91 | | |
$ | - | |
Finance Expenses: | |
| | | |
| | | |
| | |
Revaluation of SAFE instruments | |
$ | - | | |
$ | - | | |
$ | (200 | ) |
Issuance costs | |
| (439 | ) | |
| - | | |
| - | |
Exchange rates | |
| - | | |
| (22 | ) | |
| (33 | ) |
Bank fees | |
| (9 | ) | |
| (7 | ) | |
| (2 | ) |
| |
$ | (448 | ) | |
$ | (29 | ) | |
$ | (235 | ) |
| |
| | | |
| | | |
| | |
Total financing income, net | |
$ | 1,942 | | |
$ | 62 | | |
$ | (235 | ) |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 14 - Related Parties Balances and Transactions
A. | Balances with related parties: |
| |
As of December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Other payables – Officers and Directors | |
$ | 1,012 | | |
$ | 475 | |
| |
$ | 1,012 | | |
$ | 475 | |
B. | Transactions with related parties: |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Salary fees(1) | |
$ | 1,932 | | |
$ | 1,510 | | |
$ | 257 | |
Directors consultancy fees(2) | |
| 310 | | |
| 310 | | |
| 29 | |
Share based payment expense (refer to Note 10) | |
| 1,243 | | |
| 1,128 | | |
| 738 | |
| |
$ | 3,485 | | |
$ | 2,948 | | |
$ | 1,024 | |
(1) Number of related parties | |
| 5 | | |
| 3 | | |
| 3 | |
(2) Number of directors | |
| 5 | | |
| 5 | | |
| 4 | |
|
● |
Compensation packages for the Company’s executive officers, consisting of (i) an annual base salary payable in cash and (ii) a target annual bonus based on a combination of Company performance and personal goals and (iii) share based compensation (refer to Note 10(4)). |
|
● |
Compensation package for the chairman and other independent and external directors, consisting of (i) an annual retainer payable in cash, (ii) additional cash retainers for committee chairmanship and committee service, and (iii) share based compensation (refer to Note 10(4)). |
| ● | On May 10 and June 21, 2022, the Company’s board of directors and shareholders, respectively, approved a bonus plan for 2022 for the Company’s officers. The bonus plan defined specified millstones (in fields of clinic trail progress, business developments and raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus. As detailed in the plan, such bonuses (if entitled) will be paid in cash or, if the Company has less than $6 million of cash and cash equivalents and deposits on December 31, 2022, a number of ordinary shares of the Company with a value equal to the cash bonus amount to which the officer would otherwise have been entitled, valuing each ordinary share at the closing price of the Company’s shares on Nasdaq on December 31, 2022. Since the cash and cash equivalents and deposits on December 31,2022 was more than $6 million, the 2022 bonus should have been paid in cash. Based on the goals achieved as of December 31, 2022, the Company recorded a payment liability in the amount of $370 thousand which has been recorded as salary fee in the year ending December 31, 2022. In March 2023, certain officer’s 2022 bonus was replaced by issuance of RSUs and an update to 2022 annual bonus of the CEO was approved (see also Note 10). |
3. |
During March and May 2023, certain officers and directors were granted with options and RSUs, see also Note 10. |
NeuroSense Therapeutics Ltd.
Notes to the Consolidated Financial Statements
Note 15 - Income Taxes
The tax rate relevant to the Company
in the years 2023, 2022 and 2021 was 23%.
As of December 31, 2023, the Company
has net operating losses carryforward for Israeli income tax purposes of approximately $14,412, which can be offset against future taxable
income for an indefinite period of time.
The Company has
final (considered final) tax assessments through the 2018 tax year.
B. | Deferred income taxes reflect the net tax effects of net operating loss and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows: |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Net operating loss carryforward | |
$ | 3,315 | | |
$ | 1,649 | | |
$ | 717 | |
Research and development credits | |
| 1,395 | | |
| 447 | | |
| 234 | |
Operating right of use asset | |
| (35 | ) | |
| (54 | ) | |
| - | |
Operating lease liability | |
| 33 | | |
| 14 | | |
| - | |
Vacation and convalescence accrual | |
| 50 | | |
| 33 | | |
| 2 | |
Net deferred tax asset before valuation allowance | |
| 4,758 | | |
| 2,089 | | |
| 953 | |
| |
| | | |
| | | |
| | |
Valuation allowance | |
| (4,758 | ) | |
| (2,089 | ) | |
| (953 | ) |
| |
$ | - | | |
$ | - | | |
$ | - | |
In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded
a full valuation allowance as of December 31, 2023 and 2022.
C. |
During the years ended December 31, 2023, 2022 and 2021, the main reconciling item between the statutory tax rate of the Company (as noted in Note 15A1) and the effective tax rate is mainly the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carryforward and other temporary differences due to the uncertainty of the realization of such deferred taxes. |
Note 16 - Subsequent Events
Purchase Agreement
On April 10, 2024, the Company entered
into a Securities Purchase Agreement (the “Purchase Agreement”) with the institutional purchaser (the “Purchaser”),
pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchaser (i) an
aggregate of 1,732,000 ordinary shares, no par value; (ii) an aggregate of 1,248,000 pre-funded warrants, each representing the right
to acquire one ordinary share at an exercise price of $0.0001 (either physically or on a net-cash basis at the Purchaser’s discretion),
exercisable at any time upon their issuance until exercised in full and (iii) an aggregate of 2,980,000 Warrants, each representing the
right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash basis at the Purchaser’s discretion)
and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.47 million.
0.52
0.74
0.91
false
--12-31
FY
2023
2023-12-31
0001875091
0001875091
2023-01-01
2023-12-31
0001875091
2023-12-31
0001875091
2022-12-31
0001875091
2022-01-01
2022-12-31
0001875091
2021-01-01
2021-12-31
0001875091
us-gaap:CommonStockMember
2020-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001875091
us-gaap:RetainedEarningsMember
2020-12-31
0001875091
2020-12-31
0001875091
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0001875091
us-gaap:RetainedEarningsMember
2021-01-01
2021-12-31
0001875091
us-gaap:CommonStockMember
2021-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001875091
us-gaap:RetainedEarningsMember
2021-12-31
0001875091
2021-12-31
0001875091
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001875091
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001875091
us-gaap:CommonStockMember
2022-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001875091
us-gaap:RetainedEarningsMember
2022-12-31
0001875091
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-12-31
0001875091
us-gaap:RetainedEarningsMember
2023-01-01
2023-12-31
0001875091
us-gaap:CommonStockMember
2023-12-31
0001875091
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001875091
us-gaap:RetainedEarningsMember
2023-12-31
0001875091
us-gaap:ComputerSoftwareIntangibleAssetMember
2023-01-01
2023-12-31
0001875091
srt:MinimumMember
us-gaap:OfficeEquipmentMember
2023-01-01
2023-12-31
0001875091
srt:MaximumMember
us-gaap:OfficeEquipmentMember
2023-01-01
2023-12-31
0001875091
us-gaap:LeaseholdImprovementsMember
2023-01-01
2023-12-31
0001875091
currency:ILS
2023-12-31
0001875091
currency:ILS
2022-12-31
0001875091
currency:USD
2023-12-31
0001875091
currency:USD
2022-12-31
0001875091
currency:EUR
2023-12-31
0001875091
currency:EUR
2022-12-31
0001875091
currency:GBP
2023-12-31
0001875091
currency:GBP
2022-12-31
0001875091
us-gaap:ComputerEquipmentMember
2022-12-31
0001875091
us-gaap:OfficeEquipmentMember
2022-12-31
0001875091
us-gaap:LeaseholdImprovementsMember
2022-12-31
0001875091
us-gaap:ComputerEquipmentMember
2023-01-01
2023-12-31
0001875091
us-gaap:OfficeEquipmentMember
2023-01-01
2023-12-31
0001875091
us-gaap:ComputerEquipmentMember
2023-12-31
0001875091
us-gaap:OfficeEquipmentMember
2023-12-31
0001875091
us-gaap:LeaseholdImprovementsMember
2023-12-31
0001875091
us-gaap:ComputerEquipmentMember
2021-12-31
0001875091
us-gaap:OfficeEquipmentMember
2021-12-31
0001875091
us-gaap:LeaseholdImprovementsMember
2021-12-31
0001875091
us-gaap:ComputerEquipmentMember
2022-01-01
2022-12-31
0001875091
us-gaap:OfficeEquipmentMember
2022-01-01
2022-12-31
0001875091
us-gaap:LeaseholdImprovementsMember
2022-01-01
2022-12-31
0001875091
2023-06-22
0001875091
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001875091
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001875091
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001875091
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001875091
us-gaap:WarrantMember
2023-01-01
2023-12-31
0001875091
us-gaap:MeasurementInputPriceVolatilityMember
2023-12-31
0001875091
us-gaap:MeasurementInputSharePriceMember
2023-12-31
0001875091
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-12-31
0001875091
us-gaap:MeasurementInputExpectedTermMember
2023-12-31
0001875091
us-gaap:MeasurementInputExpectedDividendRateMember
2023-12-31
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-02-28
2021-02-28
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-05-31
2021-05-31
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-06-30
2021-06-30
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-07-31
2021-07-31
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-02-28
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-05-31
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-06-30
0001875091
nrsn:SimpleAgreementsForFutureEquityMember
2021-07-31
0001875091
us-gaap:WarrantMember
nrsn:SharePurchaseAgreementsMember
2020-12-31
0001875091
2021-08-31
0001875091
2021-09-30
0001875091
2021-08-31
2021-08-31
0001875091
2021-09-30
2021-09-30
0001875091
2021-05-31
2021-05-31
0001875091
2021-10-31
2021-10-31
0001875091
nrsn:OptionsMember
2023-12-31
0001875091
us-gaap:IPOMember
2021-01-01
2021-12-31
0001875091
us-gaap:CommonStockMember
us-gaap:IPOMember
2021-12-31
0001875091
us-gaap:IPOMember
2021-12-31
0001875091
nrsn:UnderwritersOptionMember
2023-01-01
2023-12-31
0001875091
2022-03-31
2022-03-31
0001875091
2022-03-31
0001875091
2023-04-14
2023-04-14
0001875091
2023-06-22
2023-06-22
0001875091
us-gaap:CommonStockMember
2023-06-22
2023-06-22
0001875091
us-gaap:WarrantMember
2023-06-22
2023-06-22
0001875091
2023-06-23
2023-06-23
0001875091
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-06-23
2023-06-23
0001875091
2023-10-31
2023-10-31
0001875091
nrsn:PreFundedWarrantsMember
2023-10-31
2023-10-31
0001875091
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0001875091
2018-12-16
2018-12-16
0001875091
srt:MinimumMember
2023-01-01
2023-12-31
0001875091
srt:MaximumMember
2023-01-01
2023-12-31
0001875091
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2021-10-31
0001875091
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2023-12-31
0001875091
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
us-gaap:CommonStockMember
2023-12-31
0001875091
srt:BoardOfDirectorsChairmanMember
2021-03-31
2021-03-31
0001875091
2021-03-31
2021-03-31
0001875091
us-gaap:IPOMember
2021-03-31
2021-03-31
0001875091
2021-12-15
2021-12-15
0001875091
2022-03-15
2022-03-15
0001875091
srt:ChiefFinancialOfficerMember
2021-07-31
2021-07-31
0001875091
2021-07-31
2021-07-31
0001875091
2022-10-31
2022-10-31
0001875091
us-gaap:RestrictedStockUnitsRSUMember
us-gaap:IPOMember
2021-12-13
2021-12-13
0001875091
us-gaap:IPOMember
2021-12-13
2021-12-13
0001875091
srt:BoardOfDirectorsChairmanMember
us-gaap:IPOMember
2021-12-13
2021-12-13
0001875091
us-gaap:IPOMember
2021-10-01
2021-10-01
0001875091
srt:DirectorMember
us-gaap:IPOMember
2021-01-01
2021-12-31
0001875091
2021-12-09
2021-12-09
0001875091
2022-06-08
2022-06-08
0001875091
2021-12-13
2021-12-13
0001875091
2022-01-11
2022-01-11
0001875091
2022-01-10
2022-01-10
0001875091
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2022-01-25
2022-01-25
0001875091
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2022-03-10
2022-03-10
0001875091
srt:DirectorMember
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2022-01-25
2022-01-25
0001875091
srt:MinimumMember
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2022-01-25
2022-01-25
0001875091
srt:MaximumMember
nrsn:TwoThousandTwentyEightEmployeeShareOptionPlanMember
2022-01-25
2022-01-25
0001875091
srt:BoardOfDirectorsChairmanMember
2022-01-25
2022-01-25
0001875091
2022-01-25
2022-01-25
0001875091
srt:BoardOfDirectorsChairmanMember
2022-03-31
2022-03-31
0001875091
nrsn:SubcontractorsAndConsultantsMember
2022-03-31
2022-03-31
0001875091
srt:BoardOfDirectorsChairmanMember
2022-07-31
2022-07-31
0001875091
srt:BoardOfDirectorsChairmanMember
2022-08-31
2022-08-31
0001875091
2022-07-31
2022-07-31
0001875091
2022-08-31
2022-08-31
0001875091
us-gaap:CommonStockMember
2022-12-31
0001875091
us-gaap:RestrictedStockUnitsRSUMember
nrsn:TwoThousandTwentyTwoBonusPlanMember
2023-03-20
2023-03-20
0001875091
nrsn:TwoThousandTwentyTwoBonusPlanMember
2023-03-20
2023-03-20
0001875091
nrsn:EmployeesAndDirectorsMember
2023-03-20
0001875091
us-gaap:RestrictedStockUnitsRSUMember
2023-03-20
0001875091
2023-03-20
2023-03-20
0001875091
srt:BoardOfDirectorsChairmanMember
2023-05-30
2023-05-30
0001875091
2023-05-30
2023-05-30
0001875091
srt:BoardOfDirectorsChairmanMember
2023-08-15
2023-08-15
0001875091
2023-08-15
2023-08-15
0001875091
us-gaap:RestrictedStockUnitsRSUMember
2023-01-01
2023-12-31
0001875091
us-gaap:RestrictedStockUnitsRSUMember
2021-01-01
2021-12-31
0001875091
us-gaap:PrivatePlacementMember
2023-01-01
2023-12-31
0001875091
us-gaap:IPOMember
2023-01-01
2023-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2023-01-01
2023-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2023-01-01
2023-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2022-01-01
2022-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2022-01-01
2022-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2021-01-01
2021-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2021-01-01
2021-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2023-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2023-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2022-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2022-12-31
0001875091
srt:MinimumMember
nrsn:EmployeesAndDirectorsMember
2021-12-31
0001875091
srt:MaximumMember
nrsn:EmployeesAndDirectorsMember
2021-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2023-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2022-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2021-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2023-01-01
2023-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2022-01-01
2022-12-31
0001875091
nrsn:EmployeesAndDirectorsMember
2021-01-01
2021-12-31
0001875091
srt:MinimumMember
2021-01-01
2021-12-31
0001875091
srt:MaximumMember
2021-01-01
2021-12-31
0001875091
srt:MinimumMember
2022-12-31
0001875091
srt:MaximumMember
2022-12-31
0001875091
srt:MinimumMember
2021-12-31
0001875091
srt:MaximumMember
2021-12-31
0001875091
srt:MinimumMember
2022-01-01
2022-12-31
0001875091
srt:MaximumMember
2022-01-01
2022-12-31
0001875091
us-gaap:WarrantMember
2021-01-01
2021-12-31
0001875091
us-gaap:WarrantMember
2021-12-31
0001875091
us-gaap:StockOptionMember
2023-01-01
0001875091
us-gaap:StockOptionMember
2023-01-01
2023-01-01
0001875091
us-gaap:StockOptionMember
2023-01-01
2023-12-31
0001875091
us-gaap:StockOptionMember
2023-12-31
0001875091
us-gaap:RestrictedStockUnitsRSUMember
2022-12-31
0001875091
us-gaap:RestrictedStockUnitsRSUMember
2022-01-01
2022-12-31
0001875091
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-12-31
0001875091
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-12-31
0001875091
us-gaap:ResearchAndDevelopmentExpenseMember
2021-01-01
2021-12-31
0001875091
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-12-31
0001875091
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-12-31
0001875091
us-gaap:GeneralAndAdministrativeExpenseMember
2021-01-01
2021-12-31
0001875091
nrsn:RevaluationOfWarrantsMember
2023-01-01
2023-12-31
0001875091
nrsn:RevaluationOfWarrantsMember
2022-01-01
2022-12-31
0001875091
nrsn:RevaluationOfWarrantsMember
2021-01-01
2021-12-31
0001875091
nrsn:DepositInterestMember
2023-01-01
2023-12-31
0001875091
nrsn:DepositInterestMember
2022-01-01
2022-12-31
0001875091
nrsn:DepositInterestMember
2021-01-01
2021-12-31
0001875091
nrsn:ExchangeRatesMember
2023-01-01
2023-12-31
0001875091
nrsn:ExchangeRatesMember
2022-01-01
2022-12-31
0001875091
nrsn:ExchangeRatesMember
2021-01-01
2021-12-31
0001875091
nrsn:RevaluationOfSAFEInstrumentsMember
2023-01-01
2023-12-31
0001875091
nrsn:RevaluationOfSAFEInstrumentsMember
2022-01-01
2022-12-31
0001875091
nrsn:RevaluationOfSAFEInstrumentsMember
2021-01-01
2021-12-31
0001875091
nrsn:IssuanceCostsMember
2023-01-01
2023-12-31
0001875091
nrsn:IssuanceCostsMember
2022-01-01
2022-12-31
0001875091
nrsn:IssuanceCostsMember
2021-01-01
2021-12-31
0001875091
nrsn:BankFeesMember
2023-01-01
2023-12-31
0001875091
nrsn:BankFeesMember
2022-01-01
2022-12-31
0001875091
nrsn:BankFeesMember
2021-01-01
2021-12-31
0001875091
srt:ChiefFinancialOfficerMember
2021-06-01
0001875091
2021-06-01
0001875091
2021-06-01
2021-06-01
0001875091
srt:OfficerMember
2022-12-31
0001875091
nrsn:OtherPayablesOfficersAndDirectorsMember
2023-12-31
0001875091
nrsn:OtherPayablesOfficersAndDirectorsMember
2022-12-31
0001875091
us-gaap:RelatedPartyMember
2023-12-31
0001875091
us-gaap:RelatedPartyMember
2022-12-31
0001875091
nrsn:SalaryFeesMember
us-gaap:RelatedPartyMember
2023-01-01
2023-12-31
0001875091
nrsn:SalaryFeesMember
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0001875091
nrsn:SalaryFeesMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001875091
nrsn:DirectorsConsultancyFeesMember
us-gaap:RelatedPartyMember
2023-01-01
2023-12-31
0001875091
nrsn:DirectorsConsultancyFeesMember
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0001875091
nrsn:DirectorsConsultancyFeesMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001875091
nrsn:ShareBasedPaymentExpenseMember
us-gaap:RelatedPartyMember
2023-01-01
2023-12-31
0001875091
nrsn:ShareBasedPaymentExpenseMember
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0001875091
nrsn:ShareBasedPaymentExpenseMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001875091
us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
2023-01-01
2023-12-31
0001875091
us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0001875091
us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001875091
us-gaap:RelatedPartyMember
2023-01-01
2023-12-31
0001875091
us-gaap:RelatedPartyMember
2022-01-01
2022-12-31
0001875091
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001875091
country:IL
2023-01-01
2023-12-31
0001875091
country:IL
2022-01-01
2022-12-31
0001875091
country:IL
2021-01-01
2021-12-31
0001875091
country:IL
2023-12-31
0001875091
srt:ScenarioForecastMember
us-gaap:CommonStockMember
2024-04-10
2024-04-10
0001875091
srt:ScenarioForecastMember
nrsn:PreFundedWarrantsMember
2024-04-10
0001875091
srt:ScenarioForecastMember
nrsn:PreFundedWarrantsMember
2024-04-10
2024-04-10
0001875091
srt:ScenarioForecastMember
us-gaap:WarrantMember
2024-04-10
0001875091
srt:ScenarioForecastMember
us-gaap:WarrantMember
2024-04-10
2024-04-10
0001875091
srt:ScenarioForecastMember
2024-04-10
2024-04-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Exhibit 99.2
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
You should read the following
selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements
and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in in accordance with generally accepted
accounting principles of the United States of America, or U.S. GAAP. Unless otherwise indicated or the context otherwise requires, all
references herein to the terms “NeuroSense,” “NeuroSense Therapeutics,” the “Company,” “we,”
“us” and “our” refer to NeuroSense Therapeutics Ltd. The term “NIS” refers to New Israeli Shekels,
the lawful currency of the State of Israel, and the terms “dollar” or “$” refer to U.S. dollars, the lawful currency
of the United States. Unless derived from our financial statements or otherwise indicated, U.S. dollar translations of NIS amounts presented
in this exhibit are translated using the rate of NIS 3.7230 to $1.00, based on the representative exchange rate reported by the Bank of
Israel on June 14, 2024.
Forward Looking Statements
This exhibit contains forward-looking
statements concerning among other things, our ongoing and planned product development and clinical trials; the timing of, and our ability
to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates; our ability to enter into and maintain
strategic collaborations, our intellectual property position; our results of operations, cash needs; financial condition, liquidity,
prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. Many of the forward-looking
statements contained in this exhibit can be identified by the use of forward-looking words such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “should,” “target,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, although not all forward-looking statements contain these identifying words.
Forward-looking statements
are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements
are subject to substantial risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking
statements due to a variety of factors, including, but not limited to, those identified under the section titled “Risk Factors”
in our Annual Report on Form 20-F, filed with the SEC on April 4, 2024, or the Annual Report, and our other filings with the SEC from time to time. These risks
and uncertainties include factors relating to:
| ● | the going concern reference in our financial statements and
our need for substantial additional financing to achieve our goals; |
| ● | our limited operating history and history of incurring significant
losses and negative cash flows since our inception, which we anticipate will continue for the foreseeable future; |
| ● | our dependence on the success of our lead product candidate,
PrimeC, including our obtaining of regulatory approval to market PrimeC in the United States; |
| ● | our limited experience in conducting clinical trials and
reliance on clinical research organizations and others to conduct them; |
| ● | our ability to advance our preclinical product candidates
into clinical development and through regulatory approval; |
| ● | the results of our clinical trials, which may fail to adequately
demonstrate the safety and efficacy of our product candidates; |
| ● | our ability to achieve the broad degree of physician adoption
and use and market acceptance necessary for commercial success; |
| ● | our reliance on third parties in marketing, producing or
distributing products and research materials for certain raw materials, compounds and components necessary to produce PrimeC for clinical
trials and to support commercial scale production of PrimeC, if approved; |
| ● | our receipt of regulatory clarity and approvals for our therapeutic
candidates and the timing of such regulatory clarity and approvals and of other regulatory filings and approvals; |
| ● | estimates of our expenses, revenues, capital requirements
and our needs for additional financing; |
| ● | our efforts to obtain, protect or enforce our patents and
other intellectual property rights related to our product candidates and technologies; |
| ● | our ability to maintain the listing of our ordinary shares
on Nasdaq; |
| ● | the impact of the public health, political and security situation
in Israel, the U.S. and other countries in which we may obtain approvals for our products or our business; and |
| ● | the impacts on our ongoing and planned trials and manufacturing
as a result of the war in Israel. |
The preceding list is not intended
to be an exhaustive list of all of our risks and uncertainties. As a result of these factors, we cannot assure you that the forward-looking
statements in this exhibit will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or
at all.
In addition, statements that
“we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon
information available to us as of the date of the 6-K that accompanies this exhibit, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all relevant information.
The forward-looking statements
and opinions contained in this exhibit are based upon information available to us as of the date of the 6-K that accompanies this exhibit
and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
relevant information. The forward-looking statements contained in this exhibit speak only as of the date of the 6-K that accompanies this
exhibit, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future
developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect
the occurrence of unanticipated events.
You should read this exhibit,
and the documents that we reference herein, completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
Overview
We are a clinical-stage biotechnology
company focused on discovering and developing treatments for patients suffering from neurodegenerative diseases, including ALS, AD and
PD. We believe these diseases represent some of the most significant unmet medical needs of our time, with limited effective therapeutic
options available. The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS
alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1 billion. Due
to the complexity of neurodegenerative diseases, our strategy is utilizing a combined therapeutic approach to target multiple disease-related
pathways.
Our lead therapeutic candidate,
PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. PrimeC
is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which are hallmarks of ALS
pathology. The FDA and the EMA have granted PrimeC orphan drug designation for the treatment of ALS. In addition, the EMA has granted
PrimeC the SME status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe PrimeC’s
multifactorial mechanism of action has the potential to significantly prolong lifespan and improve ALS patients’ quality of life,
thereby reducing the burden of this debilitating disease on both patients and healthcare systems.
We have incurred operating
losses in each year since our inception. We incurred net losses of $10.1 million and $10.5 million for the years ended December 31,
2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $26.1 million. We expect to incur significant expenses
and operating losses for the foreseeable future as we advance our product candidates from formulation development through preclinical
development and clinical trials, seek regulatory approval and pursue commercialization of any approved product candidate. In addition,
we expect that our expenses will increase substantially in connection with our ongoing activities as we:
|
● |
continue the clinical development of PrimeC; |
|
● |
continue the preclinical development of our other product candidates; |
|
● |
file an NDA seeking regulatory approval for any product candidates; |
|
● |
establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain manufacturing approval; |
|
● |
maintain, expand and protect our intellectual property portfolio; |
|
● |
add equipment and physical infrastructure to support our research and development; |
|
● |
hire additional clinical development, quality control and manufacturing personnel; |
|
● |
incur additional expenses associated with operating as a U.S. public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company; and |
|
● |
add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization. |
A. Operating Results
Revenue
We have not recognized any
revenue to date and we do not expect to generate revenue from the sale of products in the near future.
Operating Expenses
Our current operating expenses
consist primarily of research and development as well as general and administrative expenses.
Research and Development Expenses
Research and development
expenses consist primarily of:
|
● |
salaries for research and development staff and related expenses, including employee benefits and share-based compensation expenses; |
|
● |
expenses for production of our product candidates by contract manufacturers; |
|
● |
expenses paid to contract research organizations and other third parties in connection with the performance of preclinical studies, clinical trials and related expenses; |
|
● |
expenses incurred under agreements with other third parties, including subcontractors, suppliers and consultants that conduct formulation development, regulatory activities and preclinical studies; |
|
● |
expenses incurred to acquire, develop and manufacture preclinical study and clinical trial materials. |
Expenses on research activities
is recognized in profit or loss when incurred. Development expenditures, including patent registration costs, are capitalized only if
development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and we intend to and have sufficient resources to complete development and to use or sell the asset. As of December 31,
2023, no development expenditures have met the recognition criteria and thus we have expensed all of our development expenditures as incurred.
We are currently focused
on advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research
and development expenses will continue to be significant and will increase over at least the next several years as we continue to develop
our product candidates and conduct preclinical studies and clinical trials of our product candidates.
We do not believe that
it is possible at this time to accurately project total expenses required for us to reach commercialization of our product
candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with
certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product
candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially
from expectations. See “Risk Factors—Risks Related to Our Business and Strategy” in our Annual Report. In
addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be
entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
General and Administrative Expenses
General and administrative
expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human
resource functions, insurance costs, facility costs and external professional service costs, including legal, accounting, marketing and
audit services and other consulting fees.
We anticipate that our general
and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support our
continued research and development programs and the potential approval and commercialization of our product candidates. We also anticipate
that we will incur increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance
with Nasdaq and SEC requirements, director and officer insurance premiums, director compensation, and other costs associated with being
a public company.
In addition, if any of our
product candidates receives regulatory approval and if we determine to invest in building a commercial infrastructure to support the marketing
of our products, we expect to incur greater expenses.
Financing Income (Expenses), net
Our net financing expenses
(income), net consist primarily of fair value revaluation of warrants, issuance costs, interest income on deposits, interest expenses
on lease liability and differences in the exchange rate between NIS and the U.S. Dollar.
Income Taxes
We have yet to generate taxable
income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately $14.4
million as of December 31, 2023. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will
be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until
we have taxable income after the full utilization of our carry forward tax losses.
Results of Operations
Comparison of the Year Ended December 31, 2023
to the Year Ended December 31, 2022
Our results of operations
for the years ended December 31, 2023 and 2023 were as follows:
| |
For the Years Ended December 31, | |
(U.S. dollars in thousands except share and per share data) | |
2023 | | |
2022 | |
Statement of Operations: | |
| | |
| |
Research and Development Expenses | |
| 7,274 | | |
| 5,587 | |
General and Administrative Expenses | |
| 4,775 | | |
| 4,967 | |
Operating Loss | |
| 12,049 | | |
| 10,554 | |
Financing Income, net | |
| (1,942 | ) | |
| (62 | ) |
Net Loss and Comprehensive Loss | |
| 10,107 | | |
| 10,492 | |
Basic and Diluted Net Loss per Share | |
| 0.74 | | |
| 0.91 | |
Weighted average number of shares outstanding used in computing basic and diluted net loss per share | |
| 13,640,168 | | |
| 11,504,521 | |
Research and Development Expenses
The following table describes
the breakdown of our research and development expenses for the indicated periods:
| |
For the Years Ended December 31, | |
(U.S. dollars in thousands except share and per share data) | |
2023 | | |
2022 | |
Subcontractors and consultants | |
$ | 4,793 | | |
| 3,612 | |
Share-based compensation | |
| 575 | | |
| 570 | |
Salaries and social benefits | |
| 1,905 | | |
| 1,405 | |
Others | |
| 1 | | |
| - | |
Total research and development expenses | |
$ | 7,274 | | |
| 5,587 | |
Our research and development
expenses for the years ended December 31, 2023 and 2022 were $7,274 thousand and $5,587 thousand, respectively. The increase of $1,687
thousand, or 30.2%, was mainly attributed to (i) an increase of $500 thousand in salaries and social benefits, mainly due to an increase
in the number of employees, and (ii) an increase of $1,181 thousand, or 32.7% in subcontractor and consulting expenses relating to clinical
programs.
General and Administrative Expenses
The following table describes
the breakdown of our general and administrative expenses for the indicated periods:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Professional services | |
$ | 1,486 | | |
| 1,085 | |
Share-based compensation | |
| 962 | | |
| 1,158 | |
Salaries and social benefits | |
| 1,011 | | |
| 1,014 | |
Insurance | |
| 511 | | |
| 1,174 | |
Traveling abroad | |
| 164 | | |
| 165 | |
Others | |
| 641 | | |
| 371 | |
| |
$ | 4,775 | | |
| 4,967 | |
Our general and administrative
expenses for the years ended December 31, 2023 and 2022 were $4,775 thousand and $4,967 thousand, respectively. The decrease of $192 thousand,
or 3.9%, was primarily attributable to (i) a $196 thousand, or 16.9%, decrease in share-based compensation expenses due to less grants
of options and RSUs to our employees, directors and service providers, (ii) a decrease of $663 thousand, or 56.5%, in insurance costs
as a public company, and (iii) a $401 thousand, or 37%, increase in professional services expenses.
Financing Income, net
Our financing income, net
for the years ended December 31, 2023 and 2022 was $1,942 thousand and $62 thousand, respectively. The change in financing income was
primarily attributable to $2,191 thousand of revaluation of the warrants and deposit interest of $87 thousand, offset by $439 thousand
of issuance costs.
B. Liquidity and Capital Resources
Overview
Since our inception, we have
incurred losses and negative cash flows from our operations. For the year ended December 31, 2023, we incurred a net loss of approximately
$10.1 million, while net cash of approximately $8.4 million was used in our operating activities. As of December 31, 2023, we had a negative
working capital of approximately $0.5 million and an accumulated deficit of approximately $26.1 million. As of December 31, 2023, our
cash and cash equivalents totaled approximately $2.6 million.
Our financial statements
have been prepared on a going concern basis under which an entity is considered to be able to realize its assets and satisfy its liabilities
in the ordinary course of business, and our financial status creates a doubt whether we will continue as a going concern. Our future operations
are dependent upon the identification and successful completion of equity or debt financing and the achievement of profitable operations
at an indeterminate time in the future. There can be no assurances that we will be successful in completing an equity or debt financing
or in achieving or maintaining profitability. The financial statements do not give effect to any adjustments relating to the carrying
values and classification of assets and liabilities that would be necessary should we be unable to continue as a going concern.
Through December 31, 2023,
we have financed our operations primarily through our initial public offering, public and private offerings of our equity securities,
proceeds from the exercise of warrants and options, and crowd funding of equity securities. Total gross invested capital as of December
31, 2023 was approximately $25.0 million, which included ordinary shares, SAFE agreements, options and warrants to purchase ordinary shares.
In May, June and July 2021,
we received $0.80 million from SAFE agreements, in September 2021, we received an additional $1.23 million from previous investors as
a result of their exercise of outstanding warrants, in December 2021, we received gross proceeds of approximately $12.0 million from
our initial public offering, and during 2022 we received approximately $3.87 million following exercise of warrants.
In April 2023, we entered
into a sales agreement, or ATM, with A.G.P./Alliance Global Partners, or AGP, pursuant to which we may offer and sell, at our option,
up to $5,743,677 of our ordinary shares through an at-the-market equity program under which AGP agreed to act as sales agent. In June
2023, we and AGP reduced the maximum aggregate offering amount under the ATM program to $502.30, and in October 2023, we terminated the
ATM program with having sold 3,600 ordinary shares for aggregate gross proceeds of $7.2 thousand.
In June 2023, we received
additional gross proceeds of approximately $4.5 million before deducting placement agent fee and related offering expenses million from
a registered direct offering. Total issuance expenses in connection with the offering were $0.45 million.
Cash flows
The following table summarizes
our statement of cash flows for the years ended December 31, 2023 and 2022:
| |
For the Years Ended December 31, | |
(U.S. dollars in thousands except share and per share data) | |
2023 | | |
2022 | |
Net cash used in operating activities | |
$ | (8,354 | ) | |
| (7,616 | ) |
Net cash provided by (used in) investing activities | |
| 3,468 | | |
| (3,590 | ) |
Net cash provided by financing activities | |
| 3,975 | | |
| 3,774 | |
Effects of exchange rate changes on cash and cash equivalents | |
| 8 | | |
| (88 | ) |
Decrease in cash and cash equivalents | |
$ | (903 | ) | |
| (7,520 | ) |
Net cash used in operating activities
Net cash used in operating
activities was $8,354 thousand and $7,616 thousand for the years ended December 31, 2023 and 2022, respectively. The $738 thousand increase
was attributable primarily to the increase in our increase in (i) our research and development expenses relating to our clinical study
and (ii) general and administrative expenses mainly due to an increase in professional services and salary and related benefits.
Net cash provided by (used in) investing activities
Net cash provided by (used
in) investing activities was $3,468 thousand and ($3,590) thousand for the years ended December 31, 2023 and 2022, respectively. The $7,058
thousand increase was attributable primarily to changes in the investment in short-term and restricted deposits.
Net cash provided by financing activities
Net cash provided by financing
activities was $3,975 thousand and $3,774 thousand for the years ended December 31, 2023 and 2023, respectively. The increase was primarily
due to the higher proceeds from issuance of shares, warrants and pre-funded warrants in 2023 compared to the proceeds from exercise of
warrants in 2022.
Funding Requirements
Since our inception, almost
all of our resources have been dedicated to the preclinical and clinical development of our lead product candidate, PrimeC. As of December
31, 2023, we had cash and cash equivalents of $2.6 million. We believe that our existing cash and cash equivalents will not be sufficient
to fund the Company’s operations for a period of at least 12 months from the date of approval of our consolidated financial statements.
Our present and future funding
requirements will depend on many factors, including, among other things:
|
● |
the progress, timing and completion of clinical trials for PrimeC; |
|
● |
preclinical studies and clinical trials for our other product candidates; |
|
● |
the costs related to obtaining regulatory approval for PrimeC and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical trial results with respect to any of these product candidates; |
|
● |
selling, marketing and patent-related activities undertaken in connection with the commercialization of PrimeC and any of our other product candidates, and costs involved in the development of an effective sales and marketing organization; |
|
● |
the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights; |
|
● |
potential new product candidates we identify and attempt to develop; and |
|
● |
revenues we may derive either directly or in the form of royalty payments from future sales of PrimeC and any other product candidates. |
For more information as to
the risks associated with our future funding needs, see “Risk Factors — We will require substantial additional financing to
achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit,
reduce or terminate our product development, commercialization efforts or other operations” in our Annual Report.
Contractual Obligations and Commitments
As of December 31, 2023,
we did not have any material contractual obligation and commitments, except for lease agreements with respect to offices. In December
2021, we entered into an office space lease agreement in Herzilya, Israel (which commenced on January 1, 2022). Monthly rent payments
including utilities amount to approximately $7 thousand and indexed to CPI. The lease period was for 24 months with an option to extend
the lease period for additional two periods of 24 months each. We exercised the first period option, and we expect to exercise the second
option for an additional lease period.
Off-Balance Sheet Arrangements
We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Recent Offerings
On June 22, 2023, we sold
to health-care focused institutional purchaser (i) an aggregate of 1,330,000 of our ordinary shares at an offering price of $1.50 per
share and (ii) pre-funded warrants to purchase up to an aggregate of 1,670,000 ordinary shares at an offering price of $5.499 per pre-funded
warrant, in a registered direct offering. Each pre-funded warrant represented the right to purchase one ordinary shares at an exercise
price of $0.0001 per share. The pre-funded warrants were exercisable immediately and at any time until the pre-funded warrants were exercised
in full (subject to a beneficial ownership limitation set forth therein). In a concurrent private placement, we also issued an aggregate
of 3,000,000 ordinary warrants, each representing the right to acquire one ordinary share, at the same purchase price in the registered
direct offering. The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.50 per share, and will expire
on the fifth anniversary of the original issuance date. Aggregate gross proceeds from the registered direct offering and concurrent private
placement were approximately $4.5 million, before deducting the placement agent fee and related offering expenses. The offerings closed
on June 26, 2023. As of the date of this 6-K, the pre-funded warrants have been exercised in full.
Reconciliation of
IFRS to U.S. GAAP
Our audited consolidated
financial statements included in this Form 6-K are our first consolidated financial statements prepared in accordance with U.S. GAAP.
The financial statements were presented in US GAAP from date of inception.
For all periods up to and
including the year ended December 31, 2023, the Company prepared its financial statements in accordance with United States generally
accepted accounting principles. An explanation of the principal adjustments made in representing its IFRS financial statements, in order
to comply with U.S. GAAP, is provided below.
The following tables present
a reconciliation of the consolidated balance sheet as of December 31, 2023 and 2022 of IFRS compared to U.S. GAAP:
| |
| |
December 31, 2023 | |
| |
| |
IFRS | | |
GAAP Adjustments
and reclassifications | | |
U.S.
GAAP | |
| |
Note | |
USD | |
| |
| |
| | |
| | |
| |
ASSETS | |
| |
| | |
| | |
| |
| |
| |
| | |
| | |
| |
CURRENT ASSETS: | |
| |
| | |
| | |
| |
Cash and cash equivalents | |
| |
| 2,640 | | |
| - | | |
| 2,640 | |
Other receivables | |
| |
| 236 | | |
| - | | |
| 236 | |
Restricted deposits | |
| |
| 64 | | |
| - | | |
| 64 | |
| |
| |
| | | |
| | | |
| | |
Total
current assets | |
| |
| 2,916 | | |
| - | | |
| 2,916 | |
| |
| |
| | | |
| | | |
| | |
NON-CURRENT ASSETS: | |
| |
| | | |
| | | |
| | |
Operating lease right of use assets | |
i | |
| 153 | | |
| 9 | | |
| 162 | |
Property and equipment, net | |
| |
| 85 | | |
| - | | |
| 85 | |
Restricted deposit | |
| |
| 22 | | |
| - | | |
| 22 | |
| |
| |
| | | |
| | | |
| | |
Total non-current assets | |
| |
| 260 | | |
| 9 | | |
| 269 | |
| |
| |
| | | |
| | | |
| | |
Total assets | |
| |
| 3,176 | | |
| 9 | | |
| 3,185 | |
| |
| |
| | | |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| |
| | | |
| | | |
| | |
| |
| |
| | | |
| | | |
| | |
CURRENT LIABILITIES: | |
| |
| | | |
| | | |
| | |
Trade payables | |
| |
| 1,459 | | |
| - | | |
| 1,459 | |
Other payables | |
| |
| 2,000 | | |
| - | | |
| 2,000 | |
| |
| |
| | | |
| | | |
| | |
Total current liabilities | |
| |
| 3,459 | | |
| - | | |
| 3,459 | |
| |
| |
| | | |
| | | |
| | |
NON-CURRENT LIABILITIES: | |
| |
| | | |
| | | |
| | |
Long-term operating lease liability | |
| |
| 73 | | |
| - | | |
| 73 | |
Liability in respect of warrants | |
ii | |
| 1,518 | | |
| (106 | ) | |
| 1,412 | |
| |
| |
| | | |
| | | |
| | |
Total non-current liabilities | |
| |
| 1,591 | | |
| (106 | ) | |
| 1,485 | |
| |
| |
| | | |
| | | |
| | |
SHAREHOLDERS’ EQUITY: | |
iii, v | |
| | | |
| | | |
| | |
Authorized: 60,000,000 shares at December 31, 2023 and 2022;
Issued and outstanding: 15,379,042 and 11,781,963 shares at December 31, 2023 and 2022, respectively | |
| |
| - | | |
| - | | |
| - | |
Share premium and capital reserve | |
| |
| 30,192 | | |
| (5,830 | ) | |
| 24,362 | |
Accumulated deficit | |
| |
| (32,066 | ) | |
| 5,945 | | |
| (26,121 | ) |
| |
| |
| | | |
| | | |
| | |
Total
shareholders’ equity | |
| |
| (1,874 | ) | |
| 115 | | |
| (1,759 | ) |
| |
| |
| | | |
| | | |
| | |
Total liabilities and shareholders’
equity | |
| |
$ | 3,176 | | |
| 9 | | |
$ | 3,185 | |
|
|
|
|
December 31, 2022 |
|
|
|
|
|
IFRS |
|
|
GAAP
Adjustments
and
reclassifications |
|
|
U.S.
GAAP |
|
|
|
Note |
|
USD |
|
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
ASSETS: |
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents |
|
|
|
|
3,543 |
|
|
|
- |
|
|
|
3,543 |
|
Short
term deposits |
|
|
|
|
3,547 |
|
|
|
- |
|
|
|
3,547 |
|
Other
receivables |
|
|
|
|
255 |
|
|
|
- |
|
|
|
255 |
|
Restricted
deposits |
|
|
|
|
36 |
|
|
|
- |
|
|
|
36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
current assets |
|
|
|
|
7,381 |
|
|
|
- |
|
|
|
7,381 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
ASSETS: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property
and equipment, net |
|
|
|
|
77 |
|
|
|
- |
|
|
|
77 |
|
Operating
lease right of use assets |
|
|
|
|
229 |
|
|
|
7 |
|
|
|
236 |
|
Restricted
deposit |
|
|
|
|
23 |
|
|
|
|
|
|
|
23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
non-current assets |
|
|
|
|
329 |
|
|
|
7 |
|
|
|
336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
assets |
|
|
|
|
7,710 |
|
|
|
7 |
|
|
|
7,717 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade
payables |
|
|
|
|
498 |
|
|
|
- |
|
|
|
498 |
|
Other
payables |
|
|
|
|
1,228 |
|
|
|
- |
|
|
|
1,228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
current liabilities |
|
|
|
|
1,726 |
|
|
|
- |
|
|
|
1,726 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
LIABILITIES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term
operating lease liability |
|
|
|
|
147 |
|
|
|
- |
|
|
|
147 |
|
Liability
in respect of warrants |
|
|
|
|
218 |
|
|
|
(218 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Long-term liabilities |
|
|
|
|
365 |
|
|
|
(218 |
) |
|
|
147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTINGENT
LIABILITIES AND COMMITMENTS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS’
EQUITY: |
|
iii, v |
|
|
|
|
|
|
|
|
|
|
|
|
Authorized:
60,000,000 shares at December 31, 2023 and 2022; Issued and outstanding: 15,379,042 and 11,781,963 shares at December 31, 2023 and
2022, respectively |
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Share
premium and capital reserve |
|
|
|
|
26,405 |
|
|
|
(4,547 |
) |
|
|
21,858 |
|
Accumulated
deficit |
|
|
|
|
(20,786 |
) |
|
|
4,772 |
|
|
|
(16,014 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
shareholders’ equity |
|
|
|
|
5,619 |
|
|
|
225 |
|
|
|
5,844 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities and shareholders’ equity |
|
|
|
$ |
7,710 |
|
|
|
7 |
|
|
$ |
7,717 |
|
The
following table presents a reconciliation of the consolidated statement of profit or loss for the years ended December 31, 2023, 2022
and 2021 of IFRS compared to U.S. GAAP:
|
|
|
|
Year ended December 31, 2023 |
|
|
|
|
|
IFRS |
|
|
GAAP
Adjustments
and
reclassifications |
|
|
U.S.
GAAP |
|
|
|
Note |
|
USD |
|
|
|
|
|
|
|
Research and development expenses |
|
iii |
|
$ |
(7,588 |
) |
|
$ |
314 |
|
|
$ |
(7,274 |
) |
General and administrative expenses |
|
i, iii |
|
|
(5,714 |
) |
|
|
939 |
|
|
|
(4,775 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
|
|
(13,302 |
) |
|
|
1,253 |
|
|
|
(12,049 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing income, net |
|
i, ii, v |
|
|
2,022 |
|
|
|
(80 |
) |
|
|
1,942 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
$ |
(11,280 |
) |
|
$ |
1,173 |
|
|
$ |
(10,107 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
|
|
$ |
(0.83 |
) |
|
$ |
0.09 |
|
|
$ |
(0.74 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of ordinary shares used in computing basic and diluted net loss per share |
|
|
|
|
13,640,168 |
|
|
|
- |
|
|
|
13,640,168 |
|
|
|
|
|
Year ended December 31, 2022 |
|
|
|
|
|
IFRS |
|
|
GAAP
Adjustments
and
reclassifications |
|
|
U.S.
GAAP |
|
|
|
Note |
|
USD |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
iii |
|
$ |
(6,416 |
) |
|
$ |
829 |
|
|
$ |
(5,587 |
) |
General and administrative expenses |
|
i, iii |
|
|
(7,136 |
) |
|
|
2,169 |
|
|
|
(4,967 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
|
|
|
|
(13,552 |
) |
|
|
2,998 |
|
|
|
(10,554 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing income, net |
|
i, ii, v |
|
|
1,212 |
|
|
|
(1,150 |
) |
|
|
62 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
$ |
(12,340 |
) |
|
$ |
1,848 |
|
|
$ |
(10,492 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
|
|
$ |
(1.07 |
) |
|
$ |
0.16 |
|
|
$ |
(0.91 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of ordinary shares used in computing basic and diluted net loss per share |
|
|
|
|
11,504,521 |
|
|
|
- |
|
|
|
11,504,521 |
|
| |
| |
Year ended December 31, 2021 | |
| |
| |
IFRS | | |
GAAP Adjustments and reclassifications | | |
U.S. GAAP | |
| |
Note | |
USD | |
| |
| |
| | |
| |
Research and development expenses | |
iii | |
$ | (3,082 | ) | |
$ | 1,688 | | |
$ | (1,394 | ) |
General and administrative expenses | |
i, iii | |
| (2,505 | ) | |
| 914 | | |
| (1,591 | ) |
| |
| |
| | | |
| | | |
| | |
Operating loss | |
| |
| (5,587 | ) | |
| 2,602 | | |
| (2,985 | ) |
| |
| |
| | | |
| | | |
| | |
Financing income (expense), net | |
i, ii, iv, v | |
| 1,546 | | |
| (1,781 | ) | |
| (235 | ) |
| |
| |
| | | |
| | | |
| | |
Net loss | |
| |
$ | (4,041 | ) | |
$ | 821 | | |
$ | (3,220 | ) |
| |
| |
| | | |
| | | |
| | |
Basic and diluted net loss per share | |
| |
$ | (0.65 | ) | |
$ | 0.13 | | |
$ | (0.52 | ) |
| |
| |
| | | |
| | | |
| | |
Weighted average number of ordinary shares used in computing basic and diluted net loss per share | |
| |
| 6,243,411 | | |
| - | | |
| 6,243,411 | |
Notes to the main adjustments and reclassifications
made in order to comply with U.S. GAAP:
|
i. |
Operating lease right of use assets: |
Under IFRS, we have recognized depreciation
expense of operating lease right of use assets and interest expense on lease liabilities. Under U.S. GAAP we recognized a single lease
cost, calculated so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis. As a result,
as of December 31, 2023, operating lease right of use assets has increased by approximately $9 thousand, finance expenses decreased by
approximately $11 thousand and general and administrative expense increased by approximately $9 thousand for the year ended December 31,
2023. In addition, as of December 31, 2022, operating lease right of use assets has increased by approximately $7 thousand, finance expenses
decreased by approximately $15 thousand and general and administrative expense increased by approximately $9 thousand for the year ended
December 31, 2022.
|
ii. |
Warrants exercisable into shares: |
Under IFRS, we recognized certain warrants
and pre-funded warrants as a liability due to cashless exercise mechanism and certain adjustments out the control of the Company. Changes
in fair value of warrants which were classified as liability from commitment date to each reporting date were recorded as financial income
(expense) in our statement of operations and comprehensive loss. Under U.S. GAAP, we recognized certain warrants and pre-funded warrants
as part of the shareholders equity. As a result, as of December 31, 2023, warrants exercisable into shares were classified under equity,
finance income decreased by approximately $95 thousand in the year ended December 31, 2023, finance income decreased by approximately
$1,166 thousand in the year ended December 31, 2022 and finance income increased by approximately $1,580 thousand in the year ended December
31, 2021.
|
iii. |
Options exercisable into shares: |
Under IFRS, we measured the fair value
of certain options granted to consultants at each reporting period whereby cumulative catch up was recognized as stock-based compensation
expenses in our statement of operations and comprehensive loss. In addition, the determination of grant date used for measuring the fair
value of options which their vesting is subject to existence of IPO was the board of directors grant approval date. Under U.S. GAAP, the
fair value of options granted to consultants is determined at the applicable grant date with no further remeasurement at subsequent periods.
In addition, the determination of grant date used for measuring the fair value of options which their vesting is subject to existence
of IPO was the IPO date. As a result, in the year ended December 31, 2023, the research and development expenses and general and administrative
expenses decreased by $314 and $947 thousand, respectively, in the year ended December 31, 2022, the research and development expenses
and general and administrative expenses decreased by $1,022 and $2,357 thousand, respectively and in the year ended December 31, 2021,
the research and development expenses and general and administrative expenses decreased by $1,688 and $913 thousand, respectively.
|
iv. |
Simple Agreements for Future Equity (SAFE): |
Under IFRS, we classified the SAFE instrument
as part of the Company's equity at issuance date. Under U.S. GAAP, the SAFE instrument was accounted for as financial liability. As a
result, in the year ended December 31, 2021, the finance expenses increased by $200 thousand.
|
v. |
Certain reclassifications have been made to the consolidated balance sheets. Such reclassifications affect the presentation of certain items in the consolidated balance sheets, and have no impact on net loss or shareholders’ equity of the Company: Finance expenses and income - In accordance with U.S. GAAP, financial income and expense were presented net in our consolidated statements of profit or loss (although presented separately in a note). Under the IFRS, the Company has separately classified financial income and expense in its consolidated financial statements. |
C. Research and Development, Patents and Licenses
For a description of our
research and development programs and the amounts that we have incurred over the last three years pursuant to those programs, please
see “Item 5. Operating and Financial Review and Prospects — A. Operating Results — Research and Development Expenses.”
D. Trend Information
Other than as disclosed elsewhere
in this 6-K, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2023 to December
31, 2023 that are reasonably likely to have a material adverse effect on our revenue, income, profitability, liquidity or capital resources,
or that caused that disclosed financial information to be not necessarily indicative of future operating results or financial condition.
E. Critical Accounting Policies and Use of
Estimates
We describe our material
accounting policies and estimates in Note 2 to our annual consolidated financial statements contained elsewhere in this annual report.
We believe that these accounting policies and estimates are critical in order to fully understand and evaluate our financial condition
and results of operations.
We prepare our consolidated
financial statements in accordance with U.S. GAAP.
In preparing these consolidated
financial statements, management has made judgments, estimates and assumptions that affect the application of our accounting policies
and the reported amounts recognized in the financial statements. On a periodic basis, we evaluate our estimates, including those related
to share-based compensation. We base our estimates on historical experience, authoritative pronouncements and various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. For more information, please
see Note 2 to our annual consolidated financial statements contained elsewhere in this annual report.
Emerging Growth Company Status
We qualify as an “emerging
growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take
advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions
include:
|
● |
to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii) exemptions from the requirement to hold a non-binding advisory vote on executive compensation, including golden parachute compensation; |
|
● |
an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and |
|
● |
an exemption from compliance with the requirement that the Public Company Accounting Oversight Board has adopted regarding a supplement to the auditor’s report providing additional information about the audit and the financial statements. |
We may take advantage of
these exemptions for up to five years or until such earlier time that we are no longer an emerging growth company. We would cease
to be an emerging growth company upon the earliest to occur of: (i) the last day of the fiscal year in which we have total annual
gross revenues of $1.235 billion or more; (ii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the
previous three years; (iii) the date on which we are deemed to be a large accelerated filer under the rules of the SEC; or (iv) the last
day of the fiscal year following the fifth anniversary of our initial public offering. We may choose to take advantage of some but not
all of these exemptions. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the
extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.
This means that an “emerging growth company” can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies.
Exhibit 99.3
Consent of Independent
Registered Public Accounting Firm
We consent to the incorporation
by reference in the registration statements (No. 333-262480) on Form
S-8 and (Nos. 333-269306 and 333-260338) on Form F-3 of our report dated June 17, 2024, with respect to the consolidated
financial statements of NeuroSense Therapeutics Ltd.
Somekh Chaikin
Member Firm of KPMG International
Tel Aviv, Israel
June 17, 2024
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Consolidated Balance Sheets - USD ($) $ in Thousands |
Dec. 31, 2023 |
Dec. 31, 2022 |
Current assets: |
|
|
Cash and cash equivalent |
$ 2,640
|
$ 3,543
|
Short term deposits |
|
3,547
|
Other receivables |
236
|
255
|
Restricted deposits |
40
|
36
|
Total current assets |
2,916
|
7,381
|
Non-current assets: |
|
|
Property and equipment, net |
85
|
77
|
Operating right of use assets |
162
|
236
|
Restricted deposit |
22
|
23
|
Total non-current assets |
269
|
336
|
Total assets |
3,185
|
7,717
|
Current liabilities: |
|
|
Trade payables |
1,459
|
498
|
Other payables |
2,000
|
1,228
|
Total current liabilities |
3,459
|
1,726
|
Non-current liabilities: |
|
|
Operating long-term lease liability |
73
|
147
|
Liability in respect of warrants |
1,412
|
|
Total noncurrent liabilities |
1,485
|
147
|
Total liabilities |
4,944
|
1,873
|
Shareholders’ equity: |
|
|
Authorized: 60,000,000 shares at December 31, 2023 and 2022; Issued and outstanding: 15,379,042 and 11,781,963 shares at December 31, 2023 and 2022, respectively |
|
|
Share premium and capital reserve |
24,362
|
21,858
|
Accumulated deficit |
(26,121)
|
(16,014)
|
Total shareholders’ equity (deficit) |
(1,759)
|
5,844
|
Total liabilities and shareholders’ equity |
$ 3,185
|
$ 7,717
|
X |
- DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableOtherCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8
+ Details
Name: |
us-gaap_AccountsPayableTradeCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DepositsAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2
+ Details
Name: |
us-gaap_RestrictedCashAndInvestmentsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2
+ Details
Name: |
us-gaap_RestrictedCashAndInvestmentsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
Consolidated Balance Sheets (Parentheticals) - shares
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Ordinary shares, shares authorized |
60,000,000
|
60,000,000
|
Ordinary shares, shares issued |
15,379,042
|
11,781,963
|
Ordinary shares, shares outstanding |
15,379,042
|
11,781,963
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Statement [Abstract] |
|
|
|
Research and development expenses |
$ (7,274)
|
$ (5,587)
|
$ (1,394)
|
General and administrative expenses |
(4,775)
|
(4,967)
|
(1,591)
|
Operating loss |
(12,049)
|
(10,554)
|
(2,985)
|
Financing income (expenses), net |
1,942
|
62
|
(235)
|
Net loss and comprehensive loss |
$ (10,107)
|
$ (10,492)
|
$ (3,220)
|
Basic net loss per share (in Dollars per share) |
$ (0.74)
|
$ (0.91)
|
$ (0.52)
|
Weighted average number of ordinary shares used in computing basic net loss per share (in Shares) |
13,640,168
|
11,504,521
|
6,243,411
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Consolidated Statements of Changes in Equity - USD ($) $ in Thousands |
Common Stock |
Share Premium and Capital Reserve |
Accumulated Deficit |
Total |
Balance at Dec. 31, 2020 |
|
$ 2,961
|
$ (2,302)
|
$ 659
|
Balance (in Shares) at Dec. 31, 2020 |
5,582,922
|
|
|
|
Issuance of shares in respect of SAFE instruments |
|
1,000
|
|
1,000
|
Issuance of shares in respect of SAFE instruments (in Shares) |
276,672
|
|
|
|
Exercise of warrants and options |
|
1,311
|
|
1,311
|
Exercise of warrants and options (in Shares) |
3,083,940
|
|
|
|
Issuance of shares and tradable warrants, net |
|
8,969
|
|
8,969
|
Issuance of shares and tradable warrants, net (in Shares) |
2,000,000
|
|
|
|
Share based compensation |
|
2,115
|
|
2,115
|
Net loss and comprehensive loss |
|
|
(3,220)
|
(3,220)
|
Balance at Dec. 31, 2021 |
|
16,356
|
(5,522)
|
10,834
|
Balance (in Shares) at Dec. 31, 2021 |
10,943,534
|
|
|
|
Repurchase of options |
|
(96)
|
|
(96)
|
Exercise of warrants and vested RSUs |
|
3,870
|
|
3,870
|
Exercise of warrants and vested RSUs (in Shares) |
838,429
|
|
|
|
Share based compensation |
|
1,728
|
|
1,728
|
Net loss and comprehensive loss |
|
|
(10,492)
|
(10,492)
|
Balance at Dec. 31, 2022 |
|
21,858
|
(16,014)
|
$ 5,844
|
Balance (in Shares) at Dec. 31, 2022 |
11,781,963
|
|
|
11,781,963
|
Issuance of shares and pre-funded warrants, net |
|
806
|
|
$ 806
|
Issuance of shares and pre-funded warrants, net (in Shares) |
1,333,600
|
|
|
|
Exercise of pre-funded warrants, options and vested RSUs |
|
|
|
|
Exercise of pre-funded warrants, options and vested RSUs (in Shares) |
2,263,479
|
|
|
|
Share based compensation |
|
1,698
|
|
1,698
|
Net loss and comprehensive loss |
|
|
(10,107)
|
(10,107)
|
Balance at Dec. 31, 2023 |
|
$ 24,362
|
$ (26,121)
|
$ (1,759)
|
Balance (in Shares) at Dec. 31, 2023 |
15,379,042
|
|
|
15,379,042
|
X |
- DefinitionExercise of pre-funded warrants options and vested RSUs.
+ References
+ Details
Name: |
nrsn_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsOptionsAndVestedRSUs |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) prefunded warrants during the current period.
+ References
+ Details
Name: |
nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNetinShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the amount of exercise of prefunded warrants, options and vested restricted stock units.
+ References
+ Details
Name: |
nrsn_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsOptionsAndVestedRSUs |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresent the amount of issuance of shares and prefunded warrants.
+ References
+ Details
Name: |
nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of stock options.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockRepurchasedDuringPeriodValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Cash flows from operating activities |
|
|
|
Net loss for the year |
$ (10,107)
|
$ (10,492)
|
$ (3,220)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
Depreciation |
21
|
12
|
3
|
Share based compensation |
1,537
|
1,728
|
1,217
|
Revaluation of liability in respect to warrants |
(2,191)
|
|
|
Revaluation of SAFE instruments |
|
|
200
|
Loss from disposal of property and equipment |
|
|
8
|
Financing expenses (income), net |
473
|
41
|
(20)
|
Changes in assets and liabilities: |
|
|
|
Decrease in operating right of use asset |
74
|
70
|
|
Decrease in operating lease liability |
(69)
|
(95)
|
|
Decrease (increase) in other current assets |
19
|
55
|
(204)
|
Increase (decrease) in trade payables |
961
|
459
|
(16)
|
Increase (decrease) in other payables |
928
|
606
|
493
|
Net cash used in operating activities |
(8,354)
|
(7,616)
|
(1,539)
|
Cash flows from investing activities |
|
|
|
Purchase of property and equipment |
(29)
|
(70)
|
(17)
|
Redemption of (investment in) short-term deposits |
3,500
|
(3,500)
|
|
Investment in restricted deposit, net |
(3)
|
(20)
|
|
Net cash provided by (used in) investing activities |
3,468
|
(3,590)
|
(17)
|
Cash flows from financing activities |
|
|
|
Issuance of SAFE instruments |
|
|
800
|
Payment in respect of cancellation of options |
|
(96)
|
|
Exercise of warrants and options |
5
|
3,870
|
1,238
|
Issuance of shares, warrants and pre-funded warrants, net |
3,970
|
|
9,864
|
Net cash provided by financing activities |
3,975
|
3,774
|
11,902
|
Effects of exchange rate changes on cash and cash equivalents |
8
|
(88)
|
18
|
Increase (decrease) in cash and cash equivalents |
(903)
|
(7,520)
|
10,364
|
Cash and cash equivalents as at the beginning of the year |
3,543
|
11,063
|
699
|
Cash and cash equivalents as of the end of the year |
2,640
|
3,543
|
11,063
|
Non-cash investing and financing activities: |
|
|
|
Recognition of right of use assets |
|
306
|
|
Conversion of SAFE instruments |
|
|
1,000
|
Supplemental disclosure of cash flow information: |
|
|
|
Interest received |
$ 179
|
$ 49
|
|
X |
- DefinitionRepresent the amount of decrease in operating lease liability.
+ References
+ Details
Name: |
nrsn_DecreaseInOperatingLeaseLiability |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDecrease in operating right of use asset.
+ References
+ Details
Name: |
nrsn_DecreaseInOperatingRightOfUseAsset |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRepresent the amount of supplemental cash flow interest received.
+ References
+ Details
Name: |
nrsn_InterestReceived |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRecognition of right of use assets.
+ References
+ Details
Name: |
nrsn_RecognitionOfRightOfUseAssets |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRepresent the amount of redemption of (investment in) short-term deposits.
+ References
+ Details
Name: |
nrsn_RedemptionofinvestmentInShorttermDeposits |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRevaluation of liability in respect to warrants.
+ References
+ Details
Name: |
nrsn_RevaluationOfLiabilityInRespectToWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRepresent the number of revaluation of SAFE instruments.
+ References
+ Details
Name: |
nrsn_RevaluationofSAFEInstruments |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockAmountConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfPropertyPlantEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableTrade |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_OtherNoncashIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow to reacquire equity classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsForRepurchaseOfOtherEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow from the purchase of receivables classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireOtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A
+ Details
Name: |
us-gaap_ProceedsFromStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.1.1.u2
General
|
12 Months Ended |
Dec. 31, 2023 |
General [Abstract] |
|
General |
Note 1 - General
A. |
NeuroSense Therapeutics Ltd. (“NeuroSense” or the “Company”) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs. |
In addition to PrimeC, the Company
has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease, with a similar strategy of
combined products.
The Company’s ordinary shares
and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbols “NRSN” and
“NRSNW,” respectively.
B. |
The Company currently has no products approved for sale and the Company’s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company’s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. |
Based on current expected level of
operating expenditures, the Company’s cash resources as at December 31, 2023 and the cash received after the reporting period (see
also Note 16) shall not be sufficient to fund the Company’s operations for a period of at least 12 months from the approval of these
consolidated financial statements, assuming that the Company will continue its development plan in accordance with the original pipeline
and without delaying or slowing down the progress of its plans. The Company will require additional cash to fund the execution of its
mid and long-term development program. The Company anticipates raising additional funds through public or private sales of debt or equity
securities, collaborative arrangements, or some combination thereof. Whilst management is progressing with its plans to secure external
financing, these still require approval by third parties, and accordingly, there is no assurance that any such arrangement will be entered
into or that financing will be available when needed in order to allow it to continue its operations, or if available, on terms favorable
or acceptable to it.
In the event financing is not obtained,
the Company may pursue cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs
or clinical trials, these events could have a material adverse effect on its business. These factors raise significant doubt about
the Company ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company
be unable to continue as a going concern.
C. |
On October 3, 2022, the Company established a US based subsidiary, NeuroSense US Inc. (“US Subsidiary”). From establishment through December 31, 2023, the US Subsidiary had no activity. The subsidiary will perform research and development activity and engage in possible collaboration agreements. On July, 2023, the Company established a German based subsidiary, NeuroSense GmbH (“NeuroSense GmbH “). NeuroSense GmbH will perform research and development activity and engage in possible collaboration agreements. From establishment through December 31, 2023, NeuroSense GmbH had no activity. |
D. |
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets, launched extensive rocket attacks and kidnapped many Israeli civilians and soldiers. Following the attack, Israel declared war against Hamas. In parallel, border clashes between Israel and the Hezbollah terrorist group on Israel’s northern border with Lebanon intensified and may escalate into a greater regional conflict. |
All of the Company’s clinical
and pre-clinical research and development is currently being conducted outside of Israel, other than its 12-month
open label-extension (“OLE”) study of the PARADIGM trial, partially conducted in Tel Aviv, and a Phase
2 trial for Alzheimer’s disease that we conduct in Haifa, Israel. The OLE has not been affected by the war, although
the quality of the study may be adversely affected if as a result of the war patients are unable to visit the study center or the study
coordinator is not able to conduct home visits and monitor the patients. In addition, in the event of a significant escalation of
hostilities in northern Israel, there may be a delay in the planned Alzheimer trial. The Company may also elect to set
up a site in Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to numerous other sites in Europe and the
U.S., and as a result it does not expect the timeline or quality of this trial to be adversely affected by the war.
The Israel Defence Force (the “IDF”),
the national military of Israel, is a conscripted military service, subject to certain exceptions. Since October 7, 2023, the IDF has
called up several hundred thousand of its reserve forces to serve. Fourteen out of the Company’s current 16 employees are resident
in Israel. Two of its non-management employees in Israel who do not perform critical functions have been called, and additional employees
may be called, for service in the current or future wars or other armed conflicts with Hamas or other terrorist groups, and such persons
may be absent for an extended period of time. As a result, its operations in Israel may be disrupted by such absences, which disruption
may materially and adversely affect its business, prospects, financial condition and results of operations.
Although until approval of these financial
statements, the impact of the war on the Company was negligible, it is currently not possible to predict the duration or severity of the
ongoing conflict or its effects on the Company’s business, operations and financial conditions. The ongoing conflict is rapidly
evolving and developing, and could disrupt its business and operations, and hamper its ability to raise additional funds or sell its securities,
among others.
E. |
After the Company issued its annual financial
statements for 2023 in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International
Accounting Standards Board, the Company elected to change the basis of accounting used in preparing its financial statements from IFRS
to United States generally accepted accounting principles (“U.S. GAAP”). Consequently, the Company’s 2023 financial
statements including prior years financial statements for 2022 and 2021 have been re-presented in accordance with U.S. GAAP.
In these financial statements, the Company has
applied U.S. GAAP as issued by the Financial Accounting Standards Board, or FASB, on a fully retrospective basis. |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Significant Accounting Policy
|
12 Months Ended |
Dec. 31, 2023 |
Significant Accounting Policy [Abstract] |
|
Significant Accounting Policy |
Note 2 - Significant Accounting Policy
The consolidated financial statements
have been prepared in accordance accounting principles generally accepted in the United States of America (“US GAAP”).
B. | Use of estimates in preparation of consolidated financial statements |
The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company’s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company’s
operation, is the U.S. dollar (“$” or “dollar”), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.
In accordance with ASC 830, “Foreign
Currency Matters”, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.
D. | Principles of Consolidation |
The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.
E. | Cash and cash equivalents |
Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.
Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.
Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement. H. | Property and equipment |
Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.
The Company’s long-lived assets are
reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.
The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:
| |
% |
Computers and peripherals and equipment | |
33 |
Office furniture and equipment | |
7 - 15 |
Leasehold improvements | |
The shorter of the lease term and the useful life |
I. | Research and Development |
Research and development costs are
expensed as incurred.
J. | Fair Value Measurements |
The Company measures and discloses
fair value in accordance with the ASC 820, “Fair Value Measurements and Disclosures” which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.
Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.
This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
As of the reported periods, the fair
values of the Company’s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company’s
consolidated balance sheets because of their nature. K. | Concentrations of credit risk |
Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).
The Company applies ASC 842, “Leases”
under which the Company determines if an arrangement is a lease at inception. The Company’s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.
Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.
Right of Use (“ROU”) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (“IBR”) based on the information available
on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment
- Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.
M. | Commitment and contingencies |
The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter. N. | Employee benefit plans |
The Company’s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (“Section 14”), pursuant
to which all of the Company’s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee’s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2023 have been made.
The Company accounts for income taxes
in accordance with ASC 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities
under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences
reverse. Valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred tax assets is amounts
more likely than not to be realized.
The Company implements a two-step approach
to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax
return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical
merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company’s
accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did
not recognize such items in its consolidated financial statements during the reported periods and did not recognize any liability with
respect to an unrecognized tax position in its balance sheets.
Taxes which would apply in the event
of disposal of investment in foreign subsidiaries have not been considered in computing the deferred taxes, since the intention of the
Company is to hold and not to realize the investment.
P. | Stock-based compensation |
The Company’s employees’
and directors’ share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.
For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.
Q. | Basic and diluted net loss per share |
Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001 which
are exercisable immediately and fully vested RSUs outstanding during the period.
Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.
During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.
S. | Recently adopted accounting pronouncements |
| 1. | In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit
Losses (“ASC 326”): Measurement of Credit Losses on Financial Instruments” to introduce a new model for recognizing
credit losses on financial instruments based on estimated current expected credit losses, or CECL. Under the new standard, an entity is
required to estimate CECL on trade receivables at inception, based on historical information, current conditions, and reasonable and supportable
forecasts. The guidance is effective for the Company for annual periods beginning after December 15, 2022, including interim periods within
those fiscal years. Early application is permitted. The Company adopted this guidance on January 1, 2023, and there was no material impact
on the Company’s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
| 2. | In August 2020, the FASB issued ASU 2020-06 “Debt- Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”): Accounting
for Convertible Instruments and Contracts in an Entity’s Own Equity”. This guidance simplifies the accounting for certain
financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s
own equity. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per
share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15, 2023, and interim periods within
those fiscal years. The Company plan to adopt this guidance on January 1, 2024, and there was no material impact on the Company’s
consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
T. | Recently issued accounting pronouncements, not yet adopted |
As an emerging growth company, the
Jumpstart Our Business Startup Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.
| 1. | In December 2023, the FASB issued ASU 2023-09 “Improvements to Income Tax Disclosures” which improves the transparency
of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation
and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income tax disclosures effectiveness.
The guidance is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company
is currently evaluating the potential effect that the updated standard will have on the consolidated financial statement disclosures. |
| 2. | In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures” which
expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly
provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description
of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public
entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280.
The guidance is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January
1, 2025, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
financial statements and related disclosures. |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Cash and Cash Equivalent
|
12 Months Ended |
Dec. 31, 2023 |
Cash and Cash Equivalent [Abstract] |
|
Cash and cash equivalent |
Note 3 - Cash and cash equivalent
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
U.S. dollars in thousands | |
Denominated in NIS | |
$ | 107 | | |
$ | 229 | |
Denominated in USD | |
| *2,533 | | |
| 3,309 | |
Denominated in EUR | |
| - | | |
| 1 | |
Denominated in GBP | |
| - | | |
| 4 | |
| |
$ | 2,640 | | |
$ | 3,543 | |
| (*) | Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%. |
|
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Other Receivables
|
12 Months Ended |
Dec. 31, 2023 |
Other Receivables [Abstract] |
|
Other receivables |
Note 4 - Other receivables
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
U.S. dollars in thousands | |
Government agencies | |
$ | 29 | | |
$ | 24 | |
Prepaid expenses | |
| 70 | | |
| 124 | |
Other | |
| 137 | | |
| 107 | |
| |
$ | 236 | | |
$ | 255 | |
|
X |
- DefinitionThe entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Property and Equipment, Net
|
12 Months Ended |
Dec. 31, 2023 |
Property and Equipment, Net [Abstract] |
|
Property and equipment, net |
Note 5 - Property and equipment, net
Balance as of December 31, 2023:
| |
Computers and
peripherals and
equipment | | |
Office
furniture and
equipment | | |
Leasehold
improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2023 | |
$ | 66 | | |
$ | 25 | | |
$ | 3 | | |
$ | 94 | |
Purchases during the year | |
| 26 | | |
| 3 | | |
| - | | |
| 29 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 92 | | |
| 28 | | |
| 3 | | |
| 123 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2023 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
Depreciation during the year | |
| 20 | | |
| 1 | | |
| (*) | | |
| 21 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 34 | | |
| 4 | | |
| (*) | | |
| 38 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2023 | |
$ | 58 | | |
$ | 24 | | |
$ | 3 | | |
$ | 85 | |
Balance as of December 31, 2022:
| |
Computers and peripherals and
equipment | | |
Office furniture and
equipment | | |
Leasehold improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2022 | |
$ | 8 | | |
$ | 16 | | |
$ | - | | |
$ | 24 | |
Purchases during the year | |
| 58 | | |
| 9 | | |
| 3 | | |
| 70 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 66 | | |
| 25 | | |
| 3 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2022 | |
| 4 | | |
| 1 | | |
| - | | |
| 5 | |
Depreciation during the year | |
| 10 | | |
| 2 | | |
| - | | |
| 12 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2022 | |
$ | 52 | | |
$ | 22 | | |
$ | 3 | | |
$ | 77 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Operating Lease
|
12 Months Ended |
Dec. 31, 2023 |
Operating Leases [Abstract] |
|
Operating lease |
Note 6 - Operating lease
The Company has lease agreements with respect
to offices. In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent
payments including utilities amount to approximately $7 thousand and indexed to CPI. The lease period is for 24 months with an option
to extend the lease period for additional two periods of 24 months each (the first one was exercised by the Company). Accordingly, the
Company recognized in the consolidated balance sheet a right-of-use asset in the amount of $306 thousand concurrently with the recognition
of a lease liability in the same amount.
Operating lease:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Operating right of use asset | |
$ | 162 | |
Current operating lease liability | |
$ | 69 | |
Non-Current operating lease liability | |
$ | 73 | |
Total operating lease liability | |
$ | 142 | |
Maturity analysis of the Company’s lease liability:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Less than one year | |
$ | 74 | |
Two years | |
| 78 | |
| |
| | |
Total operating lease payments | |
$ | 152 | |
| |
| | |
Less: imputed interest | |
$ | (10 | ) |
| |
| | |
Present value of lease liabilities | |
$ | 142 | |
Additional information on lease
The following is a summary of weighted average
remaining lease terms and discount rate for Company’s leases:
| | December 31, 2023 | | Lease term (years) | | | 2 | | Weighted average discount rate | | | 6 | % |
Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2023, 2022 and 2021:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Lease payments | |
| 75 | | |
| 79 | | |
| - | |
| |
$ | 75 | | |
$ | 79 | | |
$ | - | |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesOperatingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Other Payables
|
12 Months Ended |
Dec. 31, 2023 |
Other Payables [Abstract] |
|
Other payables |
Note 7 - Other payables
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Employees and payroll accruals | |
$ | 1,481 | | |
$ | 751 | |
Short term lease liability | |
| 69 | | |
| 64 | |
Accrued expenses | |
| 450 | | |
| 413 | |
| |
$ | 2,000 | | |
$ | 1,228 | |
|
X |
- DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Liability in Respect of Warrants
|
12 Months Ended |
Dec. 31, 2023 |
Liability In Respect of Warrants [Abstract] |
|
Liability in respect of warrants |
Note 8 - Liability in respect of warrants
As noted in Note 9Ah below, on June 22, 2023,
the Company entered into a registered direct offering under which, inter alia, the Company issued to institutional purchaser 3,000,000
warrants, each representing the right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash
basis at the Purchaser’s discretion) and will expire on the fifth anniversary of the original issuance date. The warrants are not
considered indexed to the Company’s own stock and thus have been accounted as financial liability measured at fair-value through profit
and losses until their expiration or exercise.
The Company’s financial measured at fair
value on a recurring basis, consisted of the following types of instruments as of the following dates:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Description | |
Fair value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liability in respect of warrants | |
$ | 1,412 | | |
$ | - | | |
$ | 1,412 | (*) | |
$ | - | |
(*) | The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs: |
| |
December 31, 2023 | |
Financial liabilities: | |
| |
Expected volatility (%) | |
| 93.91 | |
Share price (in $) | |
| 0.785 | |
Risk-free interest rate (%) | |
| 3.90 | |
Expected life (years) | |
| 4.47 | |
Dividend yield (%) | |
| - | |
| |
| | |
The following table summarizes the movement in warrant liability during
the year ended December 31, 2023:
| |
2023 | |
| |
U.S. dollars in thousands | |
| |
| |
Balance as at January 1, 2023 | |
$ | - | |
Recognition of liability in respect to warrants at the initial date | |
| 3,603 | |
Revaluation of liability in respect to warrants | |
| (2,191 | ) |
Balance as at December 31, 2023 | |
$ | 1,412 | |
|
X |
- References
+ Details
Name: |
nrsn_LiabilityInRespectOfWarrantsAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_LiabilityInRespectOfWarrantsTextBlock |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Shareholders' Equity
|
12 Months Ended |
Dec. 31, 2023 |
Shareholders' Equity [Abstract] |
|
Shareholders’ Equity |
Note 9 - Shareholders’ Equity
| |
Number of shares December 31 | |
| |
Authorized 2023 | | |
Issued and outstanding 2023 | | |
Authorized 2022 | | |
Issued and outstanding 2022 | |
Ordinary shares of no par value | |
| 60,000,000 | | |
| 15,379,042 | | |
| 60,000,000 | | |
| 11,781,963 | |
| a. | In February, May, June and July 2021, the Company entered into Simple Agreements for Future Equity (each, a “SAFE”) with four separate investors for aggregate proceeds of $800 thousand. Pursuant to the terms of each SAFE, upon consummation of an equity financing, the Company will issue to each investor the number of ordinary shares equal to the purchase amount divided by the SAFE price, which is defined as the price per share equal to 80% of the equity financing valuation (to be no less than $25,000 thousand). The SAFE Agreements also provide the investor the right to automatically receive ordinary shares in the case of a liquidity event, defined as a change of control event or an initial public offering. In the case of a liquidity event the investors are entitled to the number of ordinary shares equal to the investment amount divided by the liquidity price. The liquidity price is defined as the price per share equal to the Company’s valuation at the time of the liquidity event, multiplied by 80%, and divided by the Company’s capitalization (to be no less than $25,000 thousand). The Company accounted for the SAFE instrument as financial liability in accordance with ASC 480-10. The Company recorded financial expenses in the amount of $200 thousands in 2021. |
| b. | During 2018 and 2019, the Company entered into several Share Purchase Agreements (“SPAs”) with multiple investors pursuant to which the Company issued shares and warrants. Pursuant to the SPAs, the warrants had an exercise price of $0.67 and were set to expire on December 31, 2020. During 2020, the board of directors extended the expiration period for each warrant to December 31, 2021. In September 2021, three of the warrant holders assigned all or part of their warrants to four assignees, among whom are the Company’s CFO and related parties of the Company’s CEO and CFO). |
In August and September 2021 after
the said assignments, the Company received warrant exercise notices of 1,837,500 warrants, out of the total 2,130,000 warrants
outstanding at that time. The other 292,500 warrants that were not exercised were waived by their owners. As a result of the said
exercises, the Company received aggregate proceeds of $1,225 thousand.
| c. | In May and October 2021, several option holders exercised their outstanding options to purchase 285,000 ordinary shares for a gross proceed of $10 thousand. |
| d. | In October 2021, several option holders, holding an aggregate amount of 961,440 options, signed an exercise notice for their options. The proceeds from such options exercise were approximately $76 thousand. As of December 31, 2023, the amount of $47 thousand from such exercises were recognized as other receivables. |
| e. | In December 2021, the Company closed its IPO in the United States and issued 2,000,000 units consisting of 2,000,000 Ordinary shares and 2,000,000 tradable warrants with an exercise price of $6 per share, and in term of 5 years. The total gross consideration was $12,000 thousand. The above warrants was classified to equity and the gross consideration received were allocated entirely to shareholders’ equity. Applicable issuance costs, amounting to $2,136 thousand and share-based issuance costs, amounting to $898 thousand have been allocated entirely to shareholders’ equity. In addition, the net proceeds from the exercise of underwriter’s option were $3 thousand. |
| f. | In March 2022, the Company received an amount of $3,870 thousand as a result of the exercise of 645,000 warrants at a price per share of $6. | | g. | On April 14, 2023, the Company entered into a sales agreement with Alliance Global Partners, pursuant to which the Company may offer and sell, from time to time, to or through the Alliance Global Partners as agent or principal, ordinary shares an at-the-market offering, having an aggregate offering price of up to $5,744 thousands. On June 22, 2023, the Company filed a prospectus supplement reflecting a reduction in the size of the at-the-market offering to $502 thousands. During the reporting period, the Company sold 3,600 ordinary shares for a gross proceed of $7 thousands through the at-the-market offering. Issuance expenses were equal to the proceeds received. |
| h. | On June 22, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) an aggregate of 1,330,000 ordinary shares, no par value, and (ii) an aggregate of 1,670,000 Pre-Funded warrants, each representing the right to acquire one ordinary share with exercise price of $0.0001, exercisable at any time until exercised in full and (iii) an aggregate of 3,000,000 Warrants. The Warrants are exercisable immediately upon issuance at an exercise price of $1.50 per Ordinary Share and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.5 million before deducting the placement agent fee and related offering expenses of $455 thousands. The warrant instrument is classified as liability with an original fair value in the amount of $3,603 thousands and the remaining amount of $897 thousands was attributed to the ordinary shares and pre-funded warrants and recognized in equity. The direct incremental issuance costs, amounting to $454 thousands, have been allocated in the same proportion as the gross proceeds. An amount of $365 thousands was allocated to the ordinary warrants and carried directly to profit or loss as finance expense and an amount of $91 thousands was allocated to the ordinary shares and the pre-funded warrants and recognized as a reduction of equity. | | i. | On June 23, 2023, one of the Company’s employees exercised 126,000 options into 126,000 ordinary shares for a total consideration of $5 thousands. |
| j. | During October 2023, 1,670,000 Pre-Funded warrants were exercised into 1,670,000 ordinary shares of the Company. See also Note 9Ah above. |
Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board
of directors, subject to the prior rights of holders of all classes of shares outstanding.
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Share Based Payment
|
12 Months Ended |
Dec. 31, 2023 |
Share Based Payment [Abstract] |
|
Share Based Payment |
Note 10 - Share Based Payment
On December 16, 2018, the Company’s board
of directors approved an employee share option plan (“ESOP”). According to the provisions of the ESOP, the exercise period,
exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company’s fiscal year, equal to 4% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan.
The expiration date of the options granted to
employees and directors is after 10 years from the grant date. Relating to options granted to services providers, the expiration date
of the options is between 3-10 years from the grant date. In addition, pursuant to the grant letters, the options granted to employees,
directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent
party as described in the grant letters (“Exit Event”).
On October 31, 2021, the Company’s
board of directors approved an amendment to the Company’s 2018 Employee Share Option Plan. The amendment determines that the total
number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be:
| ● | An annual increase to be added as of the first day of the Company’s fiscal year, beginning in 2022 and occurring each year thereafter through 2032, equal to 4% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the Company’s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors in its sole discretion). |
Following this amendment, the number of shares
reserved under this plan was 1,151,130. As of December 31, 2023, 233,543 ordinary shares are available for future grant.
1. | In March 2021, the Company’s board of directors approved the grant of 15,000 options to a certain service provider of the Company. The options had an exercise price of $1.67 per share. The options were to vest quarterly over one year starting June 2021. On October 31, 2021, the Company’s board of directors approved a new grant to such service provider. Accordingly, the Company granted 22,500 options with the following terms: |
| ● | 10,500 options have an exercise price of $1.67 per share. The options vest immediately upon an IPO. |
| ● | 6,000 options have an exercise price of $1.67 per share. The options vested on December 15, 2021. |
| ● | 6,000 options have an exercise price of $1.67 per share. The options vested on March 15, 2022. |
The options are exercisable if the
Company receives services from the service provider during the mentioned period.
The Company accounted the new grant
as a modification to the existing grant.
2. | In July 2021, the Company granted 21,000 options to the Company’s chief financial officer. The options have an exercise price of $0.03 per share. The options vest monthly over seven months starting June 2021. Pursuant to his employment agreement, the Company agreed that to the extent the value of such options at the Company’s IPO is less than $200,000, the Company shall grant additional options. In October 2022, the Company granted 35,980 RSU’s is respect with the above. |
3. | In August 2021, the Company’s board of directors approved the grant of 9,000 options to an employee. The options have an exercise price of $5.33 per share. The options vest quarterly over 3 years starting September 2021. |
4. |
On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved the following awards to the Company’s current management and directors subject to an IPO: |
| ● | 108,000 RSUs to each of the Company’s Chief Executive Officer and Chief Financial Officer, which vest on a quarterly basis over 3 years, commencing December 13, 2021. |
| ● | 192,000 options to the Chairman of the Board. The options vest over four years on a quarterly basis commencing October 1, 2021 at an exercise price equal to $3.51. | | | | | ● | 72,000 options to a director. The options have an exercise price of $3.51 per share. The commencement date of the Option’s is December 13, 2021 (the “Vesting Commencement Date”). The Options vest as follows: one-third vest one year from the Commencement Date and the remainder vest quarterly over the following two year period. |
5. | On October 31, 2021, the Company’s board of directors approved the grant of 108,000 options to the Company’s Chief Medical Officer. The options have an exercise price of $3.51 per share and vest on a quarterly basis over 3 years starting December 2021. |
6. |
On November 9, 2021, the Company’s board of directors approved the extension of the exercise period of options of two employees, which, pursuant to their original terms would have been expire if not exercised before the completion of the IPO. According to the grant letter, at the event of an IPO, all unvested options were fully vested, and accordingly, the remaining unrecognized expenses were recorded immediately upon such vesting. |
7. | On December 9, 2021, the underwriter (see Note 9Ae), partially exercised its right to purchase an additional 300,000 warrants for a total consideration of $3 thousands. The warrants have an exercise price of $6 per share and expire 5 years after the issuance date. These warrants were treated as issuance costs, which amounted to $681 thousand based on third party valuation, and have been recorded in equity as a reduction of the share premium. Furthermore, as part of the offering, the Company issued 100,000 warrants to the underwriters as share-based issuance costs. The warrants have an exercise price of $7.5 per share and expire 5 years after date of issuance and can be exercised after June 8, 2022. These options were also treated as issuance costs and amounted to $217 thousand based on third party valuation. |
8. | On December 13, 2021, upon the completion of the Company’s IPO, 961,440 options were exercised into shares (refer to Note 9Ad above) and 20,130 Options were expired. Those options previously granted to Company’s service providers, which, according to their grants, are vested upon a successful consummation of the IPO and the remaining unrecognized expenses were recorded immediately upon such vesting. | | | 9. | On January 10 and January 11, 2022, the Company’s entered into option settlement agreement (“Agreements”) with certain consultants of the Company. According to the Agreements, the Company exchanged 27,000 options granted to certain consultants with cash payments in the aggregate of $96 thousands. The cash payment is deemed as the sole and complete settlement of the promised options. The Company recorded an additional expense of $23 thousand for such settlement which was recorded in profit and loss. The Company recorded the settlement agreement as a reduction in share premium and capital reserve. |
10. | On January 25, 2022 and March 10, 2022, the Company’s board of directors and shareholders, respectively, approved the compensation of each of the Company’s external directors and a newly appointed director. Such compensation included the grant of 72,000 options to each such director at an exercise price of $1.43 per share (total 216,000 options to three directors), pursuant to the Company’s 2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly and becomes fully vested three years from the grant date. The options expire 10 years after grant date. |
11. | On January 25, 2022, the Company’s board of directors approved the grant of aggregate amount of 192,000 options to several employees. The options have an exercise price of $2.18 per share. The options vest quarterly over three years starting January 25, 2022. The options expire 10 years after grant date. | 12. | In March 2022, the Company’s board of directors approved the grant of aggregate amount of 36,000 options to an employee and amount of 5,000 options consultant of the Company. The options have an exercise price of $3.97 and $2.18, respectively, per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date. |
13. | In July and August 2022, the Company’s board of directors approved the grant of aggregate amount of 20,000 options to a consultant and an amount of 120,000 options to several employees of the Company. The options have an exercise price of $2.18 and $1.99, respectively, per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date. |
14. | During 2022 the Company issued 85,449 of its ordinary shares to certain consultants in exchange for their services, with fair value of $119 thousands. One of the consultants received 44,000 shares of restricted stock which were issued in 4 equal installments and subject to 2 year lock-up period. Other consultant’s shares are subject to 6 months restriction period (which ended by December 31, 2022). |
15. | On March 20, 2023, the Company’s board of directors, approved the following awards: |
| ● | Grant of 320,479 RSUs to certain officers, in lieu of cash with respect to the 2022 bonus plan grants in the amount of $161 thousand. The RSUs vest quarterly over two years with acceleration condition upon meeting certain milestones. The Company met the milestones in 2023 and therefore the vesting was accelerated accordingly. |
| ● | A bonus for certain employees in the form of 100,000 and 60,000 RSU’s. The RSUs vest on a quarterly basis over one year following the grant and on an annual basis over three years following the grant, respectively. |
| ● | In addition to the grants in accordance with the 2022 bonus plan mentioned above, a raise of additional 30% of the annual 2022 bonus will be granted to the Company’s CEO. |
| ● | The grant of 13,628 Options to a consultant of the Company in in a total fair value of $22,500. The options have an exercise price of $1.82 per share. The options will vest monthly, over 9 months commencing January 1, 2023. The options expire 10 years after their grant date. |
16. | On May 30, 2023, the Company granted 160,000 RSUs to directors of the Company. The RSUs have an exercise
price of $1.53 per share. The RSUs shall vest entirely on the first anniversary of the vesting commencement date, provided that no termination
of employment of the grantee occurs prior to such anniversary. |
17. | On August 15, 2023, the Company’s board of directors approved the grant of aggregate amount of 60,000
options to several employees. The options have an exercise price of $0.96 per share and vest quarterly over 3 years starting August 15,
2023, and (ii) the grant of 9,000 options to an employee. The options have an exercise price of $0.96 per share and vest annually over
3 years starting August 15, 2023. |
The weighted average grant date fair value of
options granted during the years ended December 31, 2023, 2022 and 2021 was $0.80, $1.40 and $4.33 per option, respectively. The
weighted average grant date fair value of RSUs granted during the years ended December 31, 2023 and 2021 was $1.75 and $3.72 per
RSU, respectively.
Stock-based compensation expenses recognized in
profit and loss as an operating expense based on fair value of the option at the grant date by using Binominal option pricing model for
employees and directors and Black and scholes pricing model for non-employees. The inputs for the valuation analysis of the share options
include several assumptions of which the most significant are the fair market value of the underlying ordinary share, the expected share
price volatility and the expected option term. Expected volatility was calculated based upon historical volatility of peer companies in
the same industry on weekly basis. Expected option term represents the period that the Company’s share options are expected to be
outstanding and is set as an exercise coefficient based on academic empirical papers. Risk-free interest rate is based on the yield from
U.S. treasury bonds with an equivalent term. Expected dividend yield assumption is based on the Company’s historical experience
and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay
cash dividends in the future. Forfeitures are recognized as they occur. The following table lists the inputs used for
calculation of fair value of the options granted to employees and directors for the years ended December 31, 2023, 2022 and 2021:
| |
2023 | |
2022 | |
2021 |
Expected volatility | |
91.80% - 93.51% | |
93.63% - 93.79% | |
91.60% - 95.01% |
Exercise price | |
0.96 - 1.99 | |
1.43 - 3.97 | |
0.03 - 5.33 |
Share price (1) | |
0.96 - 1.99 | |
1.43 - 3.97 | |
3.72 - 18.19 |
Risk-free interest rate | |
3.24% - 4.35% | |
2.12% - 2.46% | |
1.42% - 1.81% |
Dividend yield | |
0 | |
0 | |
0 |
Expected life (years) | |
10 | |
10 | |
10 |
The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2023, 2022 and 2021:
| | 2023 | | 2022 | | 2021 | Expected volatility | | 100.540% | | 93.64% | | 94.25% - 94.90% | Exercise price | | 1.82 | | 2.18 | | 1.67 | Share price (1) | | 1.82 | | 1.41 - 1.96 | | 3.72 - 15.16 | Risk-free interest rate | | 3.64% | | 1.91% - 2.91% | | 1.68% - 1.72% | Dividend yield | | 0 | | 0 | | 0 | Expected life (years) | | 10 | | 10 | | 10 |
| (1) | Share price for options granted during January 2019 - September 2020 was determined based on the implied share price in recent capital
raising and for grants after that date, in light of significant achievements in clinical trials and absence of recent fundraising reflecting
embodying the said achievements, was calculated using discounted cash flows model, with the following assumptions: projected revenues,
projected operating expenses, projected EBITDA margin, projected taxes on income and weighted-average cost of capital of 30%. From October
2021 to December 2021, the Company determined its value based on two scenarios: (i) a stay private scenario (which included a private
M&A transaction) and (ii) an IPO scenario. The DCF method was used to determine the Company’s value for the stay private scenario
and for the IPO scenario, the value was determined based on underwriters’ indication for the possible range of the share price in
the anticipated IPO. The Hybrid Method was utilized to allocate the Company’s value appropriately to determine the fair value of
its ordinary shares. The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private scenario (which included
a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the stay private and the IPO
scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions and potential volatility
in the market. From December 2021, following the completion of the Company’s underwritten IPO, the share price is based on its market
value. |
The following table lists the inputs used for calculation of fair value
of the underwriters warrants granted for the year ended December 31, 2021:
Expected volatility | | | 90.59 | % | Exercise price | | $ | 7.5 | | Share price | | $ | 3.72 | | Risk-free interest rate | | | 1.23 | % | Dividend yield | | | 0 | | Expected life | | | 5 | | The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2023 and 2022:
| | Number of | | | Weighted Average | | | Weighted average remaining | | | Intrinsic value | | | | Share Options | | | Exercise Price | | | contractual life (years) | | | U.S. dollars in thousands | | Options outstanding at January 1, 2023 | | | 1,160,500 | | | $ | 2.16 | | | | 8.76 | | | $ | 247 | | Granted | | | 82,628 | | | $ | 1.10 | | | | | | | | | | Exercised | | | (126,000 | ) | | | 0.03 | | | | | | | | | | Forfeited | | | (48,000 | ) | | $ | 2.09 | | | | | | | | | | Options outstanding at December 31, 2023 | | | 1,069,128 | | | $ | 2.30 | | | | 8.15 | | | $ | 62 | | Exercisable at December 31, 2023 | | | 652,878 | | | $ | 2.26 | | | | 8.00 | | | $ | 62 | |
The following table summarizes the RSU’s activity for the annual
periods ended on December 31, 2023 and 2022:
| |
| | |
Weighted average grant date fair value | |
| |
Number of RSUs | | |
U.S. dollars in thousands | |
Outstanding at January 1, 2023 | |
| 144,000 | | |
$ | 176 | |
Granted | |
| 640,479 | | |
| | |
Exercised | |
| (467,479 | ) | |
| | |
Outstanding at December 31, 2023 | |
| 317,000 | | |
$ | 249 | |
The share-based expense recognized in the statements of operations
were as follows:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Share-based compensation expense - Research and development | |
$ | 575 | | |
$ | 570 | | |
$ | 281 | |
Share-based compensation expense - General and administrative | |
| 962 | | |
| 1,158 | | |
| 936 | |
| |
$ | 1,537 | | |
$ | 1,728 | | |
$ | 1,217 | |
During 2021, in addition to the share-based compensation
expenses that have been recorded in profit and loss, share-based compensation in the amount of $898 thousands has been allocated to the
issuance of shares and tradable warrants and accordingly recorded as a reduction of the share premium.
As of December 31, 2023, there was $376 thousands
of unrecognized compensation expense related to unvested options and RSUs. Such unrecognized expenses will be recognized over a weighted
average period of approximately 0.59 years.
|
X |
- DefinitionThe entire disclosure for share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Research and Development Expenses
|
12 Months Ended |
Dec. 31, 2023 |
Research and Development Expenses [Abstract] |
|
Research and development expenses |
Note 11 - Research and development expenses
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Subcontractors and consultants | |
$ | 4,793 | | |
$ | 3,612 | | |
$ | 628 | |
Share-based compensation | |
| 575 | | |
| 570 | | |
| 281 | |
Salaries and social benefits (*) | |
| 1,905 | | |
| 1,405 | | |
| 447 | |
Others | |
| 1 | | |
| - | | |
| 38 | |
| |
$ | 7,274 | | |
$ | 5,587 | | |
$ | 1,394 | |
|
X |
- References
+ Details
Name: |
us-gaap_ResearchAndDevelopmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1
+ Details
Name: |
us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
General and Administrative Expenses
|
12 Months Ended |
Dec. 31, 2023 |
General and Administrative Expenses [Abstract] |
|
General and Administrative Expenses |
Note 12 - General and Administrative Expenses
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Professional services | |
$ | 1,486 | | |
$ | 1,085 | | |
$ | 372 | |
Share-based compensation | |
| 962 | | |
| 1,158 | | |
| 936 | |
Salaries and social benefits (*) | |
| 1,011 | | |
| 1,014 | | |
| 74 | |
Insurance | |
| 511 | | |
| 1,174 | | |
| 68 | |
Traveling abroad | |
| 164 | | |
| 165 | | |
| 50 | |
Others | |
| 641 | | |
| 371 | | |
| 91 | |
| |
$ | 4,775 | | |
$ | 4,967 | | |
$ | 1,591 | |
| (*) | During 2023, 2022 and 2021 the Company paid to pension funds
and to insurance companies an amount of $104 thousand, $85 thousand and $14 thousand which are included in Company’s salary expenses
under research and development and general and administrative expenses, respectively. |
|
X |
- DefinitionThe disclosure of general and administrative expenses.
+ References
+ Details
Name: |
nrsn_GeneralandAdministrativeExpensesTextBlock |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Financing Income (Expenses), Net
|
12 Months Ended |
Dec. 31, 2023 |
Financing Income (Expenses), Net [Abstract] |
|
Financing Income (expenses), net |
Note 13 - Financing Income (expenses), net
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Finance Income: | |
| | |
| | |
| |
Revaluation of warrants | |
$ | 2,191 | | |
$ | - | | |
$ | - | |
Deposit interest | |
| 178 | | |
| 91 | | |
| - | |
Exchange rates | |
| 21 | | |
| - | | |
| - | |
| |
$ | 2,390 | | |
$ | 91 | | |
$ | - | |
Finance Expenses: | |
| | | |
| | | |
| | |
Revaluation of SAFE instruments | |
$ | - | | |
$ | - | | |
$ | (200 | ) |
Issuance costs | |
| (439 | ) | |
| - | | |
| - | |
Exchange rates | |
| - | | |
| (22 | ) | |
| (33 | ) |
Bank fees | |
| (9 | ) | |
| (7 | ) | |
| (2 | ) |
| |
$ | (448 | ) | |
$ | (29 | ) | |
$ | (235 | ) |
| |
| | | |
| | | |
| | |
Total financing income, net | |
$ | 1,942 | | |
$ | 62 | | |
$ | (235 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_OtherIncomeAndExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/720/tableOfContent
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 610 -Publisher FASB -URI https://asc.fasb.org/610/tableOfContent
+ Details
Name: |
us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Related Parties Balances and Transactions
|
12 Months Ended |
Dec. 31, 2023 |
Related Parties Balances and Transactions [Abstract] |
|
Related Parties Balances and Transactions |
Note 14 - Related Parties Balances and Transactions
A. | Balances with related parties: |
| |
As of December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Other payables – Officers and Directors | |
$ | 1,012 | | |
$ | 475 | |
| |
$ | 1,012 | | |
$ | 475 | |
B. | Transactions with related parties: |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Salary fees(1) | |
$ | 1,932 | | |
$ | 1,510 | | |
$ | 257 | |
Directors consultancy fees(2) | |
| 310 | | |
| 310 | | |
| 29 | |
Share based payment expense (refer to Note 10) | |
| 1,243 | | |
| 1,128 | | |
| 738 | |
| |
$ | 3,485 | | |
$ | 2,948 | | |
$ | 1,024 | |
(1) Number of related parties | |
| 5 | | |
| 3 | | |
| 3 | |
(2) Number of directors | |
| 5 | | |
| 5 | | |
| 4 | |
1. | On June 1, 2021, the Company signed an employee agreement with its Chief Financial Officer according to which the Company will pay a monthly fee for his services. In addition, as part of the agreement, Chief Financial Officer was granted with 21,000 options (refer to Note 10(2)). Under the employment agreement, it was agreed that to the extent that economical value of the Options at such time that the Company consummates its IPO (the “Options Valuation”) will be, in the aggregate, less than $200 thousand, then the Company shall allocate to the Employee additional Options equal, in the aggregate, to the difference between the Options Valuation and $200 thousand. |
2. | On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved, among others, the following: |
|
● |
Compensation packages for the Company’s executive officers, consisting of (i) an annual base salary payable in cash and (ii) a target annual bonus based on a combination of Company performance and personal goals and (iii) share based compensation (refer to Note 10(4)). |
|
● |
Compensation package for the chairman and other independent and external directors, consisting of (i) an annual retainer payable in cash, (ii) additional cash retainers for committee chairmanship and committee service, and (iii) share based compensation (refer to Note 10(4)). |
| ● | On May 10 and June 21, 2022, the Company’s board of directors and shareholders, respectively, approved a bonus plan for 2022 for the Company’s officers. The bonus plan defined specified millstones (in fields of clinic trail progress, business developments and raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus. As detailed in the plan, such bonuses (if entitled) will be paid in cash or, if the Company has less than $6 million of cash and cash equivalents and deposits on December 31, 2022, a number of ordinary shares of the Company with a value equal to the cash bonus amount to which the officer would otherwise have been entitled, valuing each ordinary share at the closing price of the Company’s shares on Nasdaq on December 31, 2022. Since the cash and cash equivalents and deposits on December 31,2022 was more than $6 million, the 2022 bonus should have been paid in cash. Based on the goals achieved as of December 31, 2022, the Company recorded a payment liability in the amount of $370 thousand which has been recorded as salary fee in the year ending December 31, 2022. In March 2023, certain officer’s 2022 bonus was replaced by issuance of RSUs and an update to 2022 annual bonus of the CEO was approved (see also Note 10). |
3. |
During March and May 2023, certain officers and directors were granted with options and RSUs, see also Note 10. |
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Income Taxes
|
12 Months Ended |
Dec. 31, 2023 |
Income Taxes [Abstract] |
|
Income Taxes |
Note 15 - Income Taxes
The tax rate relevant to the Company
in the years 2023, 2022 and 2021 was 23%.
As of December 31, 2023, the Company
has net operating losses carryforward for Israeli income tax purposes of approximately $14,412, which can be offset against future taxable
income for an indefinite period of time.
The Company has
final (considered final) tax assessments through the 2018 tax year.
B. | Deferred income taxes reflect the net tax effects of net operating loss and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows: |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Net operating loss carryforward | |
$ | 3,315 | | |
$ | 1,649 | | |
$ | 717 | |
Research and development credits | |
| 1,395 | | |
| 447 | | |
| 234 | |
Operating right of use asset | |
| (35 | ) | |
| (54 | ) | |
| - | |
Operating lease liability | |
| 33 | | |
| 14 | | |
| - | |
Vacation and convalescence accrual | |
| 50 | | |
| 33 | | |
| 2 | |
Net deferred tax asset before valuation allowance | |
| 4,758 | | |
| 2,089 | | |
| 953 | |
| |
| | | |
| | | |
| | |
Valuation allowance | |
| (4,758 | ) | |
| (2,089 | ) | |
| (953 | ) |
| |
$ | - | | |
$ | - | | |
$ | - | |
In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded
a full valuation allowance as of December 31, 2023 and 2022.
C. |
During the years ended December 31, 2023, 2022 and 2021, the main reconciling item between the statutory tax rate of the Company (as noted in Note 15A1) and the effective tax rate is mainly the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carryforward and other temporary differences due to the uncertainty of the realization of such deferred taxes. |
|
X |
- DefinitionThe entire disclosure for income tax.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Subsequent Events
|
12 Months Ended |
Dec. 31, 2023 |
Subsequent Events [Abstract] |
|
Subsequent Events |
Note 16 - Subsequent Events
Purchase Agreement
On April 10, 2024, the Company entered
into a Securities Purchase Agreement (the “Purchase Agreement”) with the institutional purchaser (the “Purchaser”),
pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchaser (i) an
aggregate of 1,732,000 ordinary shares, no par value; (ii) an aggregate of 1,248,000 pre-funded warrants, each representing the right
to acquire one ordinary share at an exercise price of $0.0001 (either physically or on a net-cash basis at the Purchaser’s discretion),
exercisable at any time upon their issuance until exercised in full and (iii) an aggregate of 2,980,000 Warrants, each representing the
right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash basis at the Purchaser’s discretion)
and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.47 million.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Accounting Policies, by Policy (Policies)
|
12 Months Ended |
Dec. 31, 2023 |
Significant Accounting Policy [Abstract] |
|
Basis of presentation |
The consolidated financial statements
have been prepared in accordance accounting principles generally accepted in the United States of America (“US GAAP”).
|
Use of estimates in preparation of consolidated financial statements |
B. | Use of estimates in preparation of consolidated financial statements | The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company’s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
|
Functional currency |
The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company’s
operation, is the U.S. dollar (“$” or “dollar”), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.
In accordance with ASC 830, “Foreign
Currency Matters”, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.
|
Principles of Consolidation |
D. | Principles of Consolidation | The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.
|
Cash and cash equivalents |
E. | Cash and cash equivalents | Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.
|
Short-term deposits |
Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.
|
Restricted deposits |
Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.
|
Property and equipment |
H. | Property and equipment | Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss. The Company’s long-lived assets are
reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses. The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:
| |
% |
Computers and peripherals and equipment | |
33 |
Office furniture and equipment | |
7 - 15 |
Leasehold improvements | |
The shorter of the lease term and the useful life |
|
Research and Development |
I. | Research and Development | Research and development costs are
expensed as incurred.
|
Fair Value Measurements |
J. | Fair Value Measurements | The Company measures and discloses
fair value in accordance with the ASC 820, “Fair Value Measurements and Disclosures” which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data. Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category. This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. As of the reported periods, the fair
values of the Company’s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company’s
consolidated balance sheets because of their nature.
|
Concentrations of credit risk |
K. | Concentrations of credit risk | Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
|
Leases |
The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below). The Company applies ASC 842, “Leases”
under which the Company determines if an arrangement is a lease at inception. The Company’s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset. Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases. Right of Use (“ROU”) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (“IBR”) based on the information available
on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment
- Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.
|
Commitment and contingencies |
M. | Commitment and contingencies | The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.
|
Employee benefit plans |
N. | Employee benefit plans | The Company’s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (“Section 14”), pursuant
to which all of the Company’s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee’s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2023 have been made.
|
Deferred income taxes |
The Company accounts for income taxes
in accordance with ASC 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities
under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences
reverse. Valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred tax assets is amounts
more likely than not to be realized. The Company implements a two-step approach
to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax
return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical
merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company’s
accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did
not recognize such items in its consolidated financial statements during the reported periods and did not recognize any liability with
respect to an unrecognized tax position in its balance sheets. Taxes which would apply in the event
of disposal of investment in foreign subsidiaries have not been considered in computing the deferred taxes, since the intention of the
Company is to hold and not to realize the investment.
|
Stock-based compensation |
P. | Stock-based compensation | The Company’s employees’
and directors’ share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur. For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.
|
Basic and diluted net loss per share |
Q. | Basic and diluted net loss per share | Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001 which
are exercisable immediately and fully vested RSUs outstanding during the period. Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants. During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.
|
Share capital |
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.
|
Recently adopted accounting pronouncements |
S. | Recently adopted accounting pronouncements |
| 1. | In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit
Losses (“ASC 326”): Measurement of Credit Losses on Financial Instruments” to introduce a new model for recognizing
credit losses on financial instruments based on estimated current expected credit losses, or CECL. Under the new standard, an entity is
required to estimate CECL on trade receivables at inception, based on historical information, current conditions, and reasonable and supportable
forecasts. The guidance is effective for the Company for annual periods beginning after December 15, 2022, including interim periods within
those fiscal years. Early application is permitted. The Company adopted this guidance on January 1, 2023, and there was no material impact
on the Company’s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
| 2. | In August 2020, the FASB issued ASU 2020-06 “Debt- Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”): Accounting
for Convertible Instruments and Contracts in an Entity’s Own Equity”. This guidance simplifies the accounting for certain
financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s
own equity. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per
share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15, 2023, and interim periods within
those fiscal years. The Company plan to adopt this guidance on January 1, 2024, and there was no material impact on the Company’s
consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption. |
|
Recently issued accounting pronouncements, not yet adopted |
T. | Recently issued accounting pronouncements, not yet adopted | As an emerging growth company, the
Jumpstart Our Business Startup Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.
| 1. | In December 2023, the FASB issued ASU 2023-09 “Improvements to Income Tax Disclosures” which improves the transparency
of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation
and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income tax disclosures effectiveness.
The guidance is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company
is currently evaluating the potential effect that the updated standard will have on the consolidated financial statement disclosures. |
| 2. | In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures” which
expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly
provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description
of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public
entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280.
The guidance is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January
1, 2025, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated
financial statements and related disclosures. |
|
X |
- DefinitionDisclosure of accounting policy for share capital.
+ References
+ Details
Name: |
nrsn_ShareCapitalPolicyTextBlock |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for credit risk.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
+ Details
Name: |
us-gaap_ConcentrationRiskCreditRisk |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1
+ Details
Name: |
us-gaap_ConsolidationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1
+ Details
Name: |
us-gaap_EmployeeStockOwnershipPlanESOPPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
+ Details
Name: |
us-gaap_FairValueMeasurementPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
+ Details
Name: |
us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-2
+ Details
Name: |
us-gaap_ShortTermLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 980 -SubTopic 20 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481834/980-20-45-1
+ Details
Name: |
us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Cash and Cash Equivalent (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Cash and Cash Equivalent [Abstract] |
|
Schedule of Cash and Cash Equivalent |
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
U.S. dollars in thousands | |
Denominated in NIS | |
$ | 107 | | |
$ | 229 | |
Denominated in USD | |
| *2,533 | | |
| 3,309 | |
Denominated in EUR | |
| - | | |
| 1 | |
Denominated in GBP | |
| - | | |
| 4 | |
| |
$ | 2,640 | | |
$ | 3,543 | |
| (*) | Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%. |
|
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the components of cash and cash equivalents.
+ References
+ Details
Name: |
us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amounts of other current assets.
+ References
+ Details
Name: |
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Property and Equipment, Net (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Property and Equipment, Net [Abstract] |
|
Schedule of Property and Equipment, Net |
Balance as of December 31, 2023:
| |
Computers and
peripherals and
equipment | | |
Office
furniture and
equipment | | |
Leasehold
improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2023 | |
$ | 66 | | |
$ | 25 | | |
$ | 3 | | |
$ | 94 | |
Purchases during the year | |
| 26 | | |
| 3 | | |
| - | | |
| 29 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 92 | | |
| 28 | | |
| 3 | | |
| 123 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2023 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
Depreciation during the year | |
| 20 | | |
| 1 | | |
| (*) | | |
| 21 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2023 | |
| 34 | | |
| 4 | | |
| (*) | | |
| 38 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2023 | |
$ | 58 | | |
$ | 24 | | |
$ | 3 | | |
$ | 85 | |
| |
Computers and peripherals and
equipment | | |
Office furniture and
equipment | | |
Leasehold improvements | | |
Total | |
| |
U.S. dollars in thousands | |
Cost: | |
| | |
| | |
| | |
| |
Balance at January 1, 2022 | |
$ | 8 | | |
$ | 16 | | |
$ | - | | |
$ | 24 | |
Purchases during the year | |
| 58 | | |
| 9 | | |
| 3 | | |
| 70 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 66 | | |
| 25 | | |
| 3 | | |
| 94 | |
| |
| | | |
| | | |
| | | |
| | |
Accumulated depreciation: | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Balance at January 1, 2022 | |
| 4 | | |
| 1 | | |
| - | | |
| 5 | |
Depreciation during the year | |
| 10 | | |
| 2 | | |
| - | | |
| 12 | |
| |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2022 | |
| 14 | | |
| 3 | | |
| - | | |
| 17 | |
| |
| | | |
| | | |
| | | |
| | |
Depreciated cost at December 31, 2022 | |
$ | 52 | | |
$ | 22 | | |
$ | 3 | | |
$ | 77 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCostTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesOperatingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481440/840-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Subparagraph (Note 3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481418/840-10-55-40
Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1
Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-2
+ Details
Name: |
us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481161/840-30-50-1
+ Details
Name: |
us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Other Payables (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Other Payables [Abstract] |
|
Schedule of Other Payables |
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Employees and payroll accruals | |
$ | 1,481 | | |
$ | 751 | |
Short term lease liability | |
| 69 | | |
| 64 | |
Accrued expenses | |
| 450 | | |
| 413 | |
| |
$ | 2,000 | | |
$ | 1,228 | |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
+ Details
Name: |
us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Liability in Respect of Warrants (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Liability in Respect of Warrants (Tables) [Line Items] |
|
Schedule of Financial Measured at Fair Value on a Recurring Basis |
The Company’s financial measured at fair
value on a recurring basis, consisted of the following types of instruments as of the following dates:
| |
December 31, 2023 | |
| |
U.S. dollars in thousands | |
Description | |
Fair value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liability in respect of warrants | |
$ | 1,412 | | |
$ | - | | |
$ | 1,412 | (*) | |
$ | - | |
(*) | The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs: |
|
Schedule of Financial liabilities |
The following table lists the inputs used for calculation of fair value
of the underwriters warrants granted for the year ended December 31, 2021: Expected volatility | | | 90.59 | % | Exercise price | | $ | 7.5 | | Share price | | $ | 3.72 | | Risk-free interest rate | | | 1.23 | % | Dividend yield | | | 0 | | Expected life | | | 5 | |
|
Schedule of the Movement in Warrant Liability |
The following table summarizes the movement in warrant liability during
the year ended December 31, 2023:
| |
2023 | |
| |
U.S. dollars in thousands | |
| |
| |
Balance as at January 1, 2023 | |
$ | - | |
Recognition of liability in respect to warrants at the initial date | |
| 3,603 | |
Revaluation of liability in respect to warrants | |
| (2,191 | ) |
Balance as at December 31, 2023 | |
$ | 1,412 | |
|
Warrant [Member] |
|
Liability in Respect of Warrants (Tables) [Line Items] |
|
Schedule of Financial liabilities |
| |
December 31, 2023 | |
Financial liabilities: | |
| |
Expected volatility (%) | |
| 93.91 | |
Share price (in $) | |
| 0.785 | |
Risk-free interest rate (%) | |
| 3.90 | |
Expected life (years) | |
| 4.47 | |
Dividend yield (%) | |
| - | |
| |
| | |
|
X |
- References
+ Details
Name: |
nrsn_LiabilityinRespectofWarrantsTablesLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8
+ Details
Name: |
us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Shareholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Shareholders' Equity [Abstract] |
|
Schedule of Share Capital |
Share capital
| |
Number of shares December 31 | |
| |
Authorized 2023 | | |
Issued and outstanding 2023 | | |
Authorized 2022 | | |
Issued and outstanding 2022 | |
Ordinary shares of no par value | |
| 60,000,000 | | |
| 15,379,042 | | |
| 60,000,000 | | |
| 11,781,963 | |
|
X |
- DefinitionTabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Share Based Payment (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Share Based Payment [Abstract] |
|
Schedule of Fair Value of the Options Granted |
The following table lists the inputs used for
calculation of fair value of the options granted to employees and directors for the years ended December 31, 2023, 2022 and 2021:
| |
2023 | |
2022 | |
2021 |
Expected volatility | |
91.80% - 93.51% | |
93.63% - 93.79% | |
91.60% - 95.01% |
Exercise price | |
0.96 - 1.99 | |
1.43 - 3.97 | |
0.03 - 5.33 |
Share price (1) | |
0.96 - 1.99 | |
1.43 - 3.97 | |
3.72 - 18.19 |
Risk-free interest rate | |
3.24% - 4.35% | |
2.12% - 2.46% | |
1.42% - 1.81% |
Dividend yield | |
0 | |
0 | |
0 |
Expected life (years) | |
10 | |
10 | |
10 |
The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2023, 2022 and 2021: | | 2023 | | 2022 | | 2021 | Expected volatility | | 100.540% | | 93.64% | | 94.25% - 94.90% | Exercise price | | 1.82 | | 2.18 | | 1.67 | Share price (1) | | 1.82 | | 1.41 - 1.96 | | 3.72 - 15.16 | Risk-free interest rate | | 3.64% | | 1.91% - 2.91% | | 1.68% - 1.72% | Dividend yield | | 0 | | 0 | | 0 | Expected life (years) | | 10 | | 10 | | 10 |
| (1) | Share price for options granted during January 2019 - September 2020 was determined based on the implied share price in recent capital
raising and for grants after that date, in light of significant achievements in clinical trials and absence of recent fundraising reflecting
embodying the said achievements, was calculated using discounted cash flows model, with the following assumptions: projected revenues,
projected operating expenses, projected EBITDA margin, projected taxes on income and weighted-average cost of capital of 30%. From October
2021 to December 2021, the Company determined its value based on two scenarios: (i) a stay private scenario (which included a private
M&A transaction) and (ii) an IPO scenario. The DCF method was used to determine the Company’s value for the stay private scenario
and for the IPO scenario, the value was determined based on underwriters’ indication for the possible range of the share price in
the anticipated IPO. The Hybrid Method was utilized to allocate the Company’s value appropriately to determine the fair value of
its ordinary shares. The Hybrid Method considered the following future liquidity event scenarios: (1) a stay private scenario (which included
a private M&A transaction) and (2) an IPO scenario applying a probability weighting of 60% and 40% to the stay private and the IPO
scenarios, respectively, after considering the Company’s stage of development, the stage of IPO discussions and potential volatility
in the market. From December 2021, following the completion of the Company’s underwritten IPO, the share price is based on its market
value. |
|
Schedule of Fair Value of the Underwriters Warrants Granted |
The following table lists the inputs used for calculation of fair value
of the underwriters warrants granted for the year ended December 31, 2021: Expected volatility | | | 90.59 | % | Exercise price | | $ | 7.5 | | Share price | | $ | 3.72 | | Risk-free interest rate | | | 1.23 | % | Dividend yield | | | 0 | | Expected life | | | 5 | |
|
Schedule of Share Option Activity |
The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2023 and 2022: | | Number of | | | Weighted Average | | | Weighted average remaining | | | Intrinsic value | | | | Share Options | | | Exercise Price | | | contractual life (years) | | | U.S. dollars in thousands | | Options outstanding at January 1, 2023 | | | 1,160,500 | | | $ | 2.16 | | | | 8.76 | | | $ | 247 | | Granted | | | 82,628 | | | $ | 1.10 | | | | | | | | | | Exercised | | | (126,000 | ) | | | 0.03 | | | | | | | | | | Forfeited | | | (48,000 | ) | | $ | 2.09 | | | | | | | | | | Options outstanding at December 31, 2023 | | | 1,069,128 | | | $ | 2.30 | | | | 8.15 | | | $ | 62 | | Exercisable at December 31, 2023 | | | 652,878 | | | $ | 2.26 | | | | 8.00 | | | $ | 62 | |
|
Schedule of Restricted Stock Unit (RSU’s) Activity |
The following table summarizes the RSU’s activity for the annual
periods ended on December 31, 2023 and 2022:
| |
| | |
Weighted average grant date fair value | |
| |
Number of RSUs | | |
U.S. dollars in thousands | |
Outstanding at January 1, 2023 | |
| 144,000 | | |
$ | 176 | |
Granted | |
| 640,479 | | |
| | |
Exercised | |
| (467,479 | ) | |
| | |
Outstanding at December 31, 2023 | |
| 317,000 | | |
$ | 249 | |
|
Schedule of Share-Based Expense Recognized in the Statements of Operations |
The share-based expense recognized in the statements of operations
were as follows:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Share-based compensation expense - Research and development | |
$ | 575 | | |
$ | 570 | | |
$ | 281 | |
Share-based compensation expense - General and administrative | |
| 962 | | |
| 1,158 | | |
| 936 | |
| |
$ | 1,537 | | |
$ | 1,728 | | |
$ | 1,217 | |
|
X |
- DefinitionTabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3
+ Details
Name: |
srt_CondensedStatementOfComprehensiveIncomeTableTextBlock |
Namespace Prefix: |
srt_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionThe disclosure of research and development expenses.
+ References
+ Details
Name: |
nrsn_ScheduleofResearchAndDevelopmentExpensesTableTextBlock |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ResearchAndDevelopmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
General and Administrative Expenses (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
General and Administrative Expenses [Abstract] |
|
Schedule of General and Administrative Expenses |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Professional services | |
$ | 1,486 | | |
$ | 1,085 | | |
$ | 372 | |
Share-based compensation | |
| 962 | | |
| 1,158 | | |
| 936 | |
Salaries and social benefits (*) | |
| 1,011 | | |
| 1,014 | | |
| 74 | |
Insurance | |
| 511 | | |
| 1,174 | | |
| 68 | |
Traveling abroad | |
| 164 | | |
| 165 | | |
| 50 | |
Others | |
| 641 | | |
| 371 | | |
| 91 | |
| |
$ | 4,775 | | |
$ | 4,967 | | |
$ | 1,591 | |
| (*) | During 2023, 2022 and 2021 the Company paid to pension funds
and to insurance companies an amount of $104 thousand, $85 thousand and $14 thousand which are included in Company’s salary expenses
under research and development and general and administrative expenses, respectively. |
|
X |
- References
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Financing Income (Expenses), Net (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Financing Income (Expenses), Net [Abstract] |
|
Schedule of Financing Income (Expenses) |
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Finance Income: | |
| | |
| | |
| |
Revaluation of warrants | |
$ | 2,191 | | |
$ | - | | |
$ | - | |
Deposit interest | |
| 178 | | |
| 91 | | |
| - | |
Exchange rates | |
| 21 | | |
| - | | |
| - | |
| |
$ | 2,390 | | |
$ | 91 | | |
$ | - | |
Finance Expenses: | |
| | | |
| | | |
| | |
Revaluation of SAFE instruments | |
$ | - | | |
$ | - | | |
$ | (200 | ) |
Issuance costs | |
| (439 | ) | |
| - | | |
| - | |
Exchange rates | |
| - | | |
| (22 | ) | |
| (33 | ) |
Bank fees | |
| (9 | ) | |
| (7 | ) | |
| (2 | ) |
| |
$ | (448 | ) | |
$ | (29 | ) | |
$ | (235 | ) |
| |
| | | |
| | | |
| | |
Total financing income, net | |
$ | 1,942 | | |
$ | 62 | | |
$ | (235 | ) |
|
X |
- DefinitionTabular of financing income expenses.
+ References
+ Details
Name: |
nrsn_ScheduleOfFinancingIncomeExpensesTableTextBlock |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherIncomeAndExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Related Parties Balances and Transactions (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Related Parties Balances and Transactions [Abstract] |
|
Schedule of Balances with Related Parties |
A.Balances with related parties:
| |
As of December 31, | |
| |
2023 | | |
2022 | |
| |
U.S. dollars in thousands | |
Other payables – Officers and Directors | |
$ | 1,012 | | |
$ | 475 | |
| |
$ | 1,012 | | |
$ | 475 | |
|
Schedule of Transactions with Related Parties |
B.Transactions with related parties:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Salary fees(1) | |
$ | 1,932 | | |
$ | 1,510 | | |
$ | 257 | |
Directors consultancy fees(2) | |
| 310 | | |
| 310 | | |
| 29 | |
Share based payment expense (refer to Note 10) | |
| 1,243 | | |
| 1,128 | | |
| 738 | |
| |
$ | 3,485 | | |
$ | 2,948 | | |
$ | 1,024 | |
(1) Number of related parties | |
| 5 | | |
| 3 | | |
| 3 | |
(2) Number of directors | |
| 5 | | |
| 5 | | |
| 4 | |
1. | On June 1, 2021, the Company signed an employee agreement with its Chief Financial Officer according to which the Company will pay a monthly fee for his services. In addition, as part of the agreement, Chief Financial Officer was granted with 21,000 options (refer to Note 10(2)). Under the employment agreement, it was agreed that to the extent that economical value of the Options at such time that the Company consummates its IPO (the “Options Valuation”) will be, in the aggregate, less than $200 thousand, then the Company shall allocate to the Employee additional Options equal, in the aggregate, to the difference between the Options Valuation and $200 thousand. | 2. | On October 31, 2021, the Company’s board of directors recommended that the shareholders approve, and on November 7, 2021 the Company’s shareholders approved, among others, the following: |
|
X |
- DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
+ Details
Name: |
us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Income Taxes [Abstract] |
|
Schedule of Carrying Amounts of Assets and Liabilities |
Deferred income taxes reflect the net tax effects of net operating loss and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows:
| |
For the year ended December 31, | |
| |
2023 | | |
2022 | | |
2021 | |
| |
U.S. dollars in thousands | |
Net operating loss carryforward | |
$ | 3,315 | | |
$ | 1,649 | | |
$ | 717 | |
Research and development credits | |
| 1,395 | | |
| 447 | | |
| 234 | |
Operating right of use asset | |
| (35 | ) | |
| (54 | ) | |
| - | |
Operating lease liability | |
| 33 | | |
| 14 | | |
| - | |
Vacation and convalescence accrual | |
| 50 | | |
| 33 | | |
| 2 | |
Net deferred tax asset before valuation allowance | |
| 4,758 | | |
| 2,089 | | |
| 953 | |
| |
| | | |
| | | |
| | |
Valuation allowance | |
| (4,758 | ) | |
| (2,089 | ) | |
| (953 | ) |
| |
$ | - | | |
$ | - | | |
$ | - | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionPercentage of employees monthly salary.
+ References
+ Details
Name: |
nrsn_PercentageOfEmployeesMonthlySalary |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- DefinitionDescription of leasehold improvement.
+ References
+ Details
Name: |
nrsn_PublicUtilitiesPropertyPlantAndEquipmentDisclosureOfCompositeDepreciationRateForLeaseholdImprovement |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionComposite depreciation rate for public utility plants in service.
+ References
+ Details
Name: |
us-gaap_PublicUtilitiesPropertyPlantAndEquipmentDisclosureOfCompositeDepreciationRateForPlantsInService |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRate of interest on investment.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6
+ Details
Name: |
us-gaap_InvestmentInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=currency_ILS |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=currency_USD |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=currency_EUR |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=currency_GBP |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionRepresent the amount of government agencies.
+ References
+ Details
Name: |
nrsn_GovernmentAgenciesCurrent |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from parties in nontrade transactions, classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_OtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherReceivablesGrossCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_ReceivablesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Cost: |
|
|
|
Beginning balance, Cost |
$ 94
|
|
$ 24
|
Purchases during the year |
29
|
|
70
|
Ending balance, Cost |
123
|
|
94
|
Accumulated depreciation: |
|
|
|
Beginning balance, Accumulated depreciation |
17
|
|
5
|
Depreciation during the year |
21
|
|
12
|
Ending balance, Accumulated depreciation |
38
|
|
17
|
Depreciated cost |
85
|
|
77
|
Computers and peripherals and equipment [Member] |
|
|
|
Cost: |
|
|
|
Beginning balance, Cost |
66
|
|
8
|
Purchases during the year |
26
|
|
58
|
Ending balance, Cost |
92
|
|
66
|
Accumulated depreciation: |
|
|
|
Beginning balance, Accumulated depreciation |
14
|
|
4
|
Depreciation during the year |
20
|
|
10
|
Ending balance, Accumulated depreciation |
34
|
|
14
|
Depreciated cost |
58
|
|
52
|
Office furniture and equipment [Member] |
|
|
|
Cost: |
|
|
|
Beginning balance, Cost |
25
|
|
16
|
Purchases during the year |
3
|
|
9
|
Ending balance, Cost |
28
|
|
25
|
Accumulated depreciation: |
|
|
|
Beginning balance, Accumulated depreciation |
3
|
|
1
|
Depreciation during the year |
1
|
|
2
|
Ending balance, Accumulated depreciation |
4
|
|
3
|
Depreciated cost |
24
|
|
22
|
Leasehold improvements [Member] |
|
|
|
Cost: |
|
|
|
Beginning balance, Cost |
3
|
|
|
Purchases during the year |
|
|
3
|
Ending balance, Cost |
3
|
|
3
|
Accumulated depreciation: |
|
|
|
Beginning balance, Accumulated depreciation |
|
|
|
Depreciation during the year |
|
[1] |
|
Ending balance, Accumulated depreciation |
|
[1] |
|
Depreciated cost |
$ 3
|
|
$ 3
|
|
|
X |
- References
+ Details
Name: |
nrsn_AccumulatedDepreciationAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_CostAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.
+ References
+ Details
Name: |
nrsn_PropertyPlantAndEquipmentAccumulatedDepreciation |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresent the amount of property plant and equipment cost.
+ References
+ Details
Name: |
nrsn_PropertyPlantandEquipmentCost |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostDepreciationAmortizationAndDepletion |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSoldDepreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionRepresent the amount of recognized right-of-use asset.
+ References
+ Details
Name: |
nrsn_RecognizedRightOfUseAsset |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
+ Details
Name: |
us-gaap_LeaseAndRentalExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesOperatingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
us-gaap_LeaseCostAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
nrsn_ScheduleOfTheLeasePaymentsTheCompanyPaidAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePaymentsUse |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionEmployees and payroll accruals.
+ References
+ Details
Name: |
nrsn_EmployeesAndPayrollAccruals |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nrsn_ScheduleOfOtherPayablesAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShort term lease liability
+ References
+ Details
Name: |
nrsn_ShortTermLeaseLiability |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableOtherCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- DefinitionNumber of warrants purchased.
+ References
+ Details
Name: |
nrsn_ClassOfWarrantOrRightPurchaseOfWarrant |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nrsn_LiabilityInRespectOfWarrantsAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.1.1.u2
Liability in Respect of Warrants (Details) - Schedule of Financial Measured at Fair Value on a Recurring Basis - Fair Value, Recurring [Member] $ in Thousands |
Dec. 31, 2023
USD ($)
|
Fair Value [Member] |
|
|
Schedule of Financial Measured at Fair Value on a Recurring Basis [Line Item] |
|
|
Liability in respect of warrants |
$ 1,412
|
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Schedule of Financial Measured at Fair Value on a Recurring Basis [Line Item] |
|
|
Liability in respect of warrants |
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Schedule of Financial Measured at Fair Value on a Recurring Basis [Line Item] |
|
|
Liability in respect of warrants |
1,412
|
[1] |
Fair Value, Inputs, Level 3 [Member] |
|
|
Schedule of Financial Measured at Fair Value on a Recurring Basis [Line Item] |
|
|
Liability in respect of warrants |
|
|
|
|
X |
- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
nrsn_FinancialLiabilitiesAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionRecognition of liability in respect to warrants at the initial date.
+ References
+ Details
Name: |
nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRevaluation of liability in respect to warrants.
+ References
+ Details
Name: |
nrsn_RevaluationOfLiabilityInRespectToWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
Shareholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
Oct. 31, 2023 |
Jun. 23, 2023 |
Jun. 22, 2023 |
Apr. 14, 2023 |
Jun. 08, 2022 |
Mar. 31, 2022 |
Dec. 09, 2021 |
Oct. 31, 2021 |
Sep. 30, 2021 |
Aug. 31, 2021 |
Jul. 31, 2021 |
Jun. 30, 2021 |
May 31, 2021 |
Feb. 28, 2021 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial expenses |
|
|
$ 91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200
|
|
Warrants exercise price per share (in Dollars per share) |
|
|
$ 1.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise notices shares (in Shares) |
|
|
|
|
|
|
|
|
1,837,500
|
1,837,500
|
|
|
|
|
|
|
|
|
Warrants outstanding shares (in Shares) |
|
|
|
|
|
|
|
|
2,130,000
|
2,130,000
|
|
|
|
|
|
|
|
|
Warrants not exercised shares (in Shares) |
|
|
|
|
|
|
|
|
292,500
|
292,500
|
|
|
|
|
|
|
|
|
Aggregate proceeds |
|
|
|
|
|
|
|
|
$ 1,225
|
$ 1,225
|
|
|
|
|
$ 3,970
|
|
9,864
|
|
Outstanding options to purchase ordinary shares (in Shares) |
|
|
|
|
|
|
|
285,000
|
|
|
|
|
285,000
|
|
|
|
|
|
Gross proceed |
|
|
|
|
|
|
|
$ 10
|
|
|
|
|
$ 10
|
|
|
|
800
|
|
Options aggregate amount (in Shares) |
|
|
|
|
|
|
|
961,440
|
|
|
|
|
|
|
|
|
|
|
Options exercise amount |
|
|
|
|
|
|
|
$ 76
|
|
|
|
|
|
|
5
|
3,870
|
1,238
|
|
Exercises other receivables |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 236
|
$ 255
|
|
|
Share-based issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 898
|
|
Net proceeds from the exercise |
|
|
|
|
$ 217
|
|
$ 681
|
|
|
|
|
|
|
|
|
|
|
|
Received amount |
|
|
|
|
|
$ 3,870
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise shares (in Shares) |
|
|
|
|
|
645,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Price per share (in Dollars per share) |
|
|
|
|
|
$ 6
|
|
|
|
|
|
|
|
|
|
|
|
|
Offering price amount |
|
|
$ 455
|
$ 5,744
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market offering price |
|
|
$ 502
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of ordinary shares (in Shares) |
|
126,000
|
|
|
|
|
|
|
|
|
|
|
|
|
3,600
|
|
|
|
Gross proceed market offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7
|
|
|
|
Aggregate ordinary shares (in Shares) |
|
|
1,330,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-funded warrants (in Shares) |
1,670,000
|
|
1,670,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate warrants (in Shares) |
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Placement agent fee |
|
|
$ 4,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value amount |
|
|
3,603
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remaining amount |
|
|
897
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incremental issuance costs |
|
|
454
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocated amount to ordinary warrants |
|
|
$ 365
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employees exercised shares (in Shares) |
|
126,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total consideration amount |
|
$ 5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Simple Agreements for Future Equity [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investors for aggregate proceeds |
|
|
|
|
|
|
|
|
|
|
$ 800
|
$ 800
|
$ 800
|
$ 800
|
|
|
|
|
Percentage of price per share |
|
|
|
|
|
|
|
|
|
|
80.00%
|
80.00%
|
80.00%
|
80.00%
|
|
|
|
|
Amount of equity financing valuation |
|
|
|
|
|
|
|
|
|
|
$ 25,000
|
$ 25,000
|
$ 25,000
|
$ 25,000
|
|
|
|
|
Valuation of liquidity event multiplied divided percentage |
|
|
|
|
|
|
|
|
|
|
80.00%
|
80.00%
|
80.00%
|
80.00%
|
|
|
|
|
Capitalization amount |
|
|
|
|
|
|
|
|
|
|
$ 25,000
|
$ 25,000
|
$ 25,000
|
$ 25,000
|
|
|
|
|
Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Untill exercised. (in Dollars per share) |
|
|
$ 1.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants [Member] | Share Purchase Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.67
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares consisting (in Shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85,449
|
|
|
Voting rights |
|
|
one
|
|
|
|
|
|
|
|
|
|
|
|
one
|
|
|
|
Untill exercised. (in Dollars per share) |
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercises other receivables |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 47
|
|
|
|
IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued units (in Shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
Tradable warrants shares (in Shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
Warrants exercise price per shares (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6
|
|
Warrants term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
Gross consideration amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 12,000
|
|
Issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,136
|
|
Share-based issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 898
|
|
IPO [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares consisting (in Shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
Underwriters Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds from the exercise |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3
|
|
|
|
Pre-Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of ordinary shares (in Shares) |
1,670,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- References
+ Details
Name: |
nrsn_AggregateWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_AllocatedAmountToOrdinaryWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of employees exercised shares.
+ References
+ Details
Name: |
nrsn_EmployeesExercisedShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of gross consideration.
+ References
+ Details
Name: |
nrsn_GrossConsiderationAmount |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of gross Proceed market offering.
+ References
+ Details
Name: |
nrsn_GrossProceedMarketOffering |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of incremental issuance costs.
+ References
+ Details
Name: |
nrsn_IncrementalIssuanceCosts |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of market offering price.
+ References
+ Details
Name: |
nrsn_MarketOfferingPrice |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of ordinary shares.
+ References
+ Details
Name: |
nrsn_NumberOfOrdinaryShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of other warrants shares not exercised were waived shares.
+ References
+ Details
Name: |
nrsn_NumberofOtherWarrantsShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of offering price amount.
+ References
+ Details
Name: |
nrsn_OfferingPriceAmount |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionOptions aggregate amount.
+ References
+ Details
Name: |
nrsn_OptionsAggregateAmount |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares outstanding options to purchase ordinary shares.
+ References
+ Details
Name: |
nrsn_OutstandingOptionstoPurchaseOrdinaryShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of price per share.
+ References
+ Details
Name: |
nrsn_PercentageOfPricePerShare |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of pre-funded warrants.
+ References
+ Details
Name: |
nrsn_PreFundedWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_ReceivedAmount |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_RemainingAmount |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of share-based issuance costs.
+ References
+ Details
Name: |
nrsn_ShareBasedIssuanceCosts |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_ShareholdersEquityDetailsLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued units.
+ References
+ Details
Name: |
nrsn_SharesIssuedUnits |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValuation of Liquidity event multiplied divided percentage.
+ References
+ Details
Name: |
nrsn_ValuationOfLiquidityEventMultipliedDividedPercentage |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of warrants exercise shares.
+ References
+ Details
Name: |
nrsn_WarrantsExerciseShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_WarrantsOrExercisePrice |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferred1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of consolidated capitalization which comprises long-term debt and equity instruments.
+ References
+ Details
Name: |
us-gaap_CapitalizationLongtermDebtAndEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightUnissued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_CommonStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
+ Details
Name: |
us-gaap_DeferredFinanceCostsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before valuation allowance, of financing receivable classified as held-for-sale.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 948 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477011/948-310-45-1
+ Details
Name: |
us-gaap_LoansReceivableHeldForSaleAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherReceivablesGrossCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromDebtNetOfIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOrSaleOfEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A
+ Details
Name: |
us-gaap_ProceedsFromStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_SharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=nrsn_OptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=nrsn_UnderwritersOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=nrsn_PreFundedWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Shareholders' Equity (Details) - Schedule of Share Capital - shares
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Schedule of Share Capital [Abstract] |
|
|
Ordinary shares of no par value, Authorized |
60,000,000
|
60,000,000
|
Ordinary shares of no par value, Issued and outstanding |
15,379,042
|
11,781,963
|
X |
- References
+ Details
Name: |
nrsn_ScheduleOfShareCapitalAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.1.1.u2
Share Based Payment (Details) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
Aug. 15, 2023 |
May 30, 2023 |
Mar. 20, 2023 |
Oct. 31, 2022 |
Aug. 31, 2022 |
Jul. 31, 2022 |
Jun. 08, 2022 |
Mar. 31, 2022 |
Mar. 15, 2022 |
Mar. 10, 2022 |
Jan. 25, 2022 |
Jan. 11, 2022 |
Jan. 10, 2022 |
Dec. 15, 2021 |
Dec. 13, 2021 |
Dec. 09, 2021 |
Oct. 31, 2021 |
Oct. 01, 2021 |
Aug. 31, 2021 |
Jul. 31, 2021 |
Mar. 31, 2021 |
Dec. 16, 2018 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Jun. 01, 2021 |
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total number of shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
4.00%
|
|
|
Expiration date grant term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
Share option granted |
9,000
|
|
13,628
|
35,980
|
|
|
|
|
6,000
|
|
|
27,000
|
|
6,000
|
20,130
|
|
108,000
|
|
9,000
|
200,000
|
22,500
|
|
|
|
|
|
Share exercise price (in Dollars per share) |
$ 0.96
|
$ 1.53
|
$ 1.82
|
|
$ 1.99
|
$ 2.18
|
$ 7.5
|
$ 2.18
|
$ 1.67
|
|
$ 2.18
|
|
|
$ 1.67
|
|
$ 6
|
$ 3.51
|
|
$ 5.33
|
$ 0.03
|
$ 1.67
|
|
$ 0.8
|
$ 1.4
|
$ 4.33
|
|
Option vested quarterly term |
|
|
9 months
|
|
1 year
|
3 years
|
|
1 year
|
|
|
3 years
|
|
|
|
|
|
3 years
|
|
3 years
|
|
|
|
7 months 2 days
|
|
|
|
Purchase of additional warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000
|
|
Total consideration (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3
|
|
Warrants expire after the issuance |
|
|
10 years
|
|
10 years
|
10 years
|
5 years
|
10 years
|
|
|
10 years
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
Issuance costs (in Dollars) |
|
|
|
|
|
|
$ 217,000
|
|
|
|
|
|
|
|
|
$ 681,000
|
|
|
|
|
|
|
|
|
|
|
Issue of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
Cash payment (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
$ 96,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
$ 23,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of shares (in Dollars) |
|
|
$ 22,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 119,000
|
|
|
Shares of restricted stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44,000
|
|
|
Number of installments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
|
Installments lock-up period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
Additional annual bonus percentage |
|
|
30.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of capital percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.00%
|
|
|
|
Share-based compensation amount (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 898,000
|
|
Compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 376,000
|
|
|
|
Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration date options term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
|
|
|
Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration date options term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
2018 Employee Share Option Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
900,000
|
|
|
|
|
|
1,151,130
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
72,000
|
72,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
$ 1.43
|
$ 1.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants expire after the issuance |
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018 Employee Share Option Plan [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option vested quarterly term |
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018 Employee Share Option Plan [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option vested quarterly term |
|
|
|
|
|
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022 Bonus Plan Grants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
161,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
640,479
|
|
|
Share exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.75
|
|
$ 3.72
|
|
Company granted |
|
|
60,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Units (RSUs) [Member] | 2022 Bonus Plan Grants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
320,479
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
60,000
|
160,000
|
|
|
120,000
|
20,000
|
|
36,000
|
|
|
192,000
|
|
|
|
|
|
|
|
|
|
15,000
|
|
|
|
|
|
Share exercise price (in Dollars per share) |
$ 0.96
|
|
|
|
|
|
|
$ 3.97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,000
|
|
|
|
|
|
|
Company granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,000
|
Director [Member] | 2018 Employee Share Option Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
216,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Board of Directors [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employees [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company granted |
|
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85,449
|
|
|
Common Stock [Member] | 2018 Employee Share Option Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
233,543
|
|
|
|
IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
961,440
|
|
|
|
|
|
10,500
|
|
|
|
|
|
Share exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.51
|
|
|
$ 1.67
|
|
|
|
$ 3.51
|
|
Option vested quarterly term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
Probability weighting percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40.00%
|
|
|
|
Share-based compensation amount (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 898,000
|
|
IPO [Member] | Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
108,000
|
|
|
|
|
|
|
|
|
|
|
|
IPO [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
192,000
|
|
|
|
|
|
|
|
|
|
|
|
IPO [Member] | Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share option granted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72,000
|
|
IPO [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share Based Payment (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Probability weighting percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60.00%
|
|
|
|
X |
- Definitionadditional annual bonus percentage.
+ References
+ Details
Name: |
nrsn_AdditionalAnnualBonusPercentage |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the expiration date grant term.
+ References
+ Details
Name: |
nrsn_ExpirationDateGrantTerm |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the expiration date options term.
+ References
+ Details
Name: |
nrsn_ExpirationDateOptionsTerm |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionInstallments lock-up period.
+ References
+ Details
Name: |
nrsn_InstallmentsLockUpPeriod |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the share value of issue of warrants.
+ References
+ Details
Name: |
nrsn_IssueOfWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares percentage.
+ References
+ Details
Name: |
nrsn_NumberOfSharesPercentage |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionProbability weighting percentage.
+ References
+ Details
Name: |
nrsn_ProbabilityWeightingPercentage |
Namespace Prefix: |
nrsn_ |
Data Type: |
dtr:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the shares value additional warrants.
+ References
+ Details
Name: |
nrsn_PurchaseOfAdditionalWarrants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of share-based issuance costs.
+ References
+ Details
Name: |
nrsn_ShareBasedIssuanceCosts |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_ShareBasedPaymentDetailsLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe compensation expense recognized during the period pertaining to the deferred compensation arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cost capitalized for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe percentage of weighted average cost inventory present at the reporting date when inventory is valued using different valuation methods.
+ References
+ Details
Name: |
us-gaap_PercentageOfWeightedAverageCostInventory |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromDebtNetOfIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cost expensed and capitalized for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_SharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares related to Restricted Stock Award forfeited during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=nrsn_TwoThousandTwentyEightEmployeeShareOptionPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=nrsn_TwoThousandTwentyTwoBonusPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=nrsn_SubcontractorsAndConsultantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=nrsn_EmployeesAndDirectorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
nrsn_ShareBasedPaymentDetailsScheduleofFairValueoftheOptionsGrantedLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=nrsn_EmployeesAndDirectorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Share Based Payment (Details) - Schedule of Share Option Activity - Equity Option [Member] - USD ($) $ / shares in Units, $ in Thousands |
|
12 Months Ended |
Jan. 01, 2023 |
Dec. 31, 2023 |
Share Based Payment (Details) - Schedule of Share Option Activity [Line Items] |
|
|
Number of Share Options,Outstanding Beginning |
1,160,500,000
|
1,069,128,000
|
Weighted Average Exercise Price,Outstanding Beginning |
$ 2.16
|
$ 2.3
|
Weighted average remaining contractual life (years) ,Outstanding Beginning |
8 years 9 months 3 days
|
8 years 1 month 24 days
|
Intrinsic value,Outstanding Beginning |
$ 247
|
$ 62
|
Number of Share Options, Exercisable |
|
652,878,000
|
Weighted Average Exercise Price, Exercisable |
|
$ 2.26
|
EWeighted average remaining contractual life (years), Exercisable |
|
8 years
|
Intrinsic value, Exercisable |
|
$ 62
|
Number of Share Options, Granted |
|
82,628,000
|
Weighted Average Exercise Price, Granted |
|
$ 1.1
|
Number of Share Options, Exercised |
|
(126,000,000)
|
Weighted Average Exercise Price, Exercised |
|
$ 0.03
|
Number of Share Options, Forfeited |
|
(48,000,000)
|
Weighted Average Exercise Price, Forfeited |
|
$ 2.09
|
X |
- DefinitionNumber of Share Options, Forfeited.
+ References
+ Details
Name: |
nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_ShareBasedPaymentDetailsScheduleofShareOptionActivityLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ References
+ Details
Name: |
nrsn_StockIssuedDuringPeriodSharesStockOptionExercised |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Share Based Payment (Details) - Schedule of Restricted Stock Unit (RSU’s) Activity - RSU’s [Member] $ / shares in Thousands |
12 Months Ended |
Dec. 31, 2022
$ / shares
shares
|
Share Based Payment (Details) - Schedule of Restricted Stock Unit (RSU’s) Activity [Line Items] |
|
Shares, Outstanding beginning |
144,000
|
Weighted average grant date fair value, Outstanding beginning (in Dollars per share) | $ / shares |
$ 176
|
Shares, Granted |
640,479
|
Shares, Exercised |
(467,479)
|
Shares, Outstanding ending |
317,000
|
Weighted average grant date fair value, ending (in Dollars per share) | $ / shares |
$ 249
|
X |
- References
+ Details
Name: |
nrsn_ShareBasedPaymentDetailsScheduleofRestrictedStockUnitRSUsActivityLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SEC
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3
Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11
+ Details
Name: |
srt_CondensedStatementOfIncomeCaptionsLineItems |
Namespace Prefix: |
srt_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Research and Development Expenses (Details) - Schedule of Research and Development Expenses - Research and Development Expenses [Member] - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Schedule of Research and Development Expenses [Line Items] |
|
|
|
Subcontractors and consultants |
$ 4,793
|
$ 3,612
|
$ 628
|
Share-based compensation |
575
|
570
|
281
|
Salaries and social benefits |
1,905
|
1,405
|
447
|
Others |
1
|
|
38
|
Research and development expenses |
$ 7,274
|
$ 5,587
|
$ 1,394
|
X |
- References
+ Details
Name: |
nrsn_ScheduleOfResearchAndDevelopmentExpensesLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent of the subcontractors and consultants.
+ References
+ Details
Name: |
nrsn_SubcontractorsandConsultants |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of other research and development expense.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
+ Details
Name: |
us-gaap_OtherResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.1.1.u2
General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses - General and Administrative Expenses [Member] - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Schedule of General and Administrative Expenses [Line Items] |
|
|
|
|
Professional services |
|
$ 1,486
|
$ 1,085
|
$ 372
|
Share-based compensation |
|
962
|
1,158
|
936
|
Salaries and social benefits |
[1] |
1,011
|
1,014
|
74
|
Insurance |
|
511
|
1,174
|
68
|
Traveling abroad |
|
164
|
165
|
50
|
Others |
|
641
|
371
|
91
|
Total |
|
$ 4,775
|
$ 4,967
|
$ 1,591
|
|
|
X |
- References
+ Details
Name: |
nrsn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_DividendsShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralInsuranceExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of general and administrative expense classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details
Name: |
us-gaap_OtherGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionProfessional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.
+ References
+ Details
Name: |
us-gaap_ProfessionalAndContractServicesExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- References
+ Details
Name: |
nrsn_FinanceExpensesAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nrsn_FinanceIncomeAbstract |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncome |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_RevaluationOfWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_DepositInterestMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_ExchangeRatesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_RevaluationOfSAFEInstrumentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_IssuanceCostsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=nrsn_BankFeesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionCarrying amount of items included in each line item in the statement of financial position that are not eligible for the fair value option.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
+ Details
Name: |
us-gaap_FairValueOptionIneligibleItemsAggregateCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_RestrictedCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_OfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
X |
- DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableOtherCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
Related Parties Balances and Transactions (Details) - Schedule of Transactions with Related Parties - Related Party [Member] $ in Thousands |
12 Months Ended |
Dec. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
Related Party Transaction [Line Items] |
|
|
|
|
(1) Number of related parties |
|
5
|
3
|
3
|
(2) Number of directors |
|
5
|
5
|
4
|
Salary fees [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Transactions with related parties |
[1] |
$ 1,932
|
$ 1,510
|
$ 257
|
Directors consultancy fees [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Transactions with related parties |
[2] |
310
|
310
|
29
|
Share based payment expense [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Transactions with related parties |
|
1,243
|
1,128
|
738
|
Related Party [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Transactions with related parties |
|
$ 3,485
|
$ 2,948
|
$ 1,024
|
|
|
X |
- Definition
+ References
+ Details
Name: |
nrsn_NumberOfDirectorsinShares |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.1.1.u2
X |
- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3
+ Details
Name: |
us-gaap_OperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=country_IL |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.1.1.u2
Income Taxes (Details) - Schedule of Carrying Amounts of Assets and Liabilities - USD ($) $ in Thousands |
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Schedule of Carrying Amounts of Assets and Liabilities [Abstract] |
|
|
|
Net operating loss carryforward |
$ 3,315
|
$ 1,649
|
$ 717
|
Research and development credits |
1,395
|
447
|
234
|
Operating right of use asset |
(35)
|
(54)
|
|
Operating lease liability |
33
|
14
|
|
Vacation and convalescence accrual |
50
|
33
|
2
|
Net deferred tax asset before valuation allowance |
4,758
|
2,089
|
953
|
Valuation allowance |
(4,758)
|
(2,089)
|
(953)
|
Total |
|
|
|
X |
- DefinitionRepresent the amount of deferred tax assets operating lease liabilities.
+ References
+ Details
Name: |
nrsn_DeferredTaxAssetsOperatingLeaseLiabilities |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRepresent the amount of deferred tax assets operating lease right of use asset.
+ References
+ Details
Name: |
nrsn_DeferredTaxAssetsOperatingLeaseRightOfUseAsset |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionVacation and convalescence accrual.
+ References
+ Details
Name: |
nrsn_VacationAndConvalescenceAccrual |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6
+ Details
Name: |
us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsLiabilitiesNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.1.1.u2
X |
- DefinitionNumber of ordinary share.
+ References
+ Details
Name: |
nrsn_NumberOfOrdinaryShare |
Namespace Prefix: |
nrsn_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCash received from sale of investments in debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_ProceedsFromSaleOfSecuritiesOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_StatementScenarioAxis=srt_ScenarioForecastMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=nrsn_PreFundedWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
NeuroSense Therapeutics (NASDAQ:NRSNW)
過去 株価チャート
から 5 2024 まで 6 2024
NeuroSense Therapeutics (NASDAQ:NRSNW)
過去 株価チャート
から 6 2023 まで 6 2024